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Abstract
Coincident with the increasing use of fluoroquinolones (FQs) as the first-line agent for treatment of urinary
tract infections (UTIs) in adults, the prevalence of high MIC fluoroquinolone susceptible E. coli (high MIC-
FQSEC) which are the E. coli isolates with reduced susceptibility to FQs has increased substantially. The high
MIC-FQSEC strains may serve as an important reservoir for FQ resistance in that treatment of these
organisms with a FQ has been associated with future emergence of resistance.
To establish an effective program for controlling emergence of FQ resistance, it is necessary to understand the
risk factors for, and impact of infection caused by high MIC-FQSEC. To identify risk factors for high MIC-FQ
susceptibility, we conducted a case-control study of female subjects with UTIs caused by FQSEC at
outpatient services within University of Pennsylvania Health System, Philadelphia. A total of 1836 subjects
with low MIC-FQSEC UTI (CASE) and 165 subjects with high MIC-FQSEC UTIs (CONTROL) were
enrolled into our study. Independent risk factors for high MIC-FQ included Asian race, having renal diseases
and previous exposure to nitrofurantoin.
To determine the impact of high MIC-FQ susceptibility, we conducted a retrospective cohort study of female
subjects with ambulatory FQSEC UTIs who were treated with FQ therapy. We enrolled 246 subjects into the
low MIC (unexposed) group and 29 subjects into the high MIC (exposed) group. Study subjects with high
MIC-FQSEC-UTIs were approximately 8 times more likely to experience treatment failure when received FQ
therapy when comparing to those with low MIC FQSEC-UTIs.
The last dissertation project was a simulation study aiming to quantitatively compare the conventional case-
control (CC) approach and the novel case-case-control (CCC) approach in investigating risk factors for
infection caused by FQ-resistant pathogen. Our study confirmed that the CC approach almost always
overestimates the effect of previous antibiotic exposure. The difference is more pronounced if the study is to
be conducted among healthy population with a lower rate of colonization and protective effect of exposure on
mechanism of harboring FQ-susceptible pathogen does not exist.
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ABSTRACT 
 
RISK FACTORS FOR AND IMPACT OF  
AMBULATORY URINARY TRACT INFECTIONS  
CAUSED BY HIGH MIC-FLUOROQUINOLONE SUSCEPTIBLE E. COLI IN WOMEN 
Pinyo Rattanaumpawan 
Ebbing Lautenbach 
Coincident with the increasing use of fluoroquinolones (FQs) as the first-line agent for treatment 
of urinary tract infections (UTIs) in adults, the prevalence of high MIC fluoroquinolone 
susceptible E. coli (high MIC-FQSEC) which are the E. coli isolates with reduced susceptibility to 
FQs has increased substantially. The high MIC-FQSEC strains may serve as an important 
reservoir for FQ resistance in that treatment of these organisms with a FQ has been associated 
with future emergence of resistance.  
 To establish an effective program for controlling emergence of FQ resistance, it is 
necessary to understand the risk factors for, and impact of infection caused by high MIC-FQSEC. 
To identify risk factors for high MIC-FQ susceptibility, we conducted a case-control study of 
female subjects with UTIs caused by FQSEC at outpatient services within University of 
Pennsylvania Health System, Philadelphia.  A total of 1836 subjects with low MIC-FQSEC UTI 
(CASE) and 165 subjects with high MIC-FQSEC UTIs (CONTROL) were enrolled into our study. 
Independent risk factors for high MIC-FQ included Asian race, having renal diseases and 
previous exposure to nitrofurantoin.  
 To determine the impact of high MIC-FQ susceptibility, we conducted a retrospective 
cohort study of female subjects with ambulatory FQSEC UTIs who were treated with FQ therapy.  
We enrolled 246 subjects into the low MIC (unexposed) group and 29 subjects into the high MIC 
(exposed) group. Study subjects with high MIC-FQSEC-UTIs were approximately 8 times more 
likely to experience treatment failure when received FQ therapy when comparing to those with 
low MIC FQSEC-UTIs.   
iii 
 
 The last dissertation project was a simulation study aiming to quantitatively compare the 
conventional case-control (CC) approach and the novel case-case-control (CCC) approach in 
investigating risk factors for infection caused by FQ-resistant pathogen.  Our study confirmed that 
the CC approach almost always overestimates the effect of previous antibiotic exposure. The 
difference is more pronounced if the study is to be conducted among healthy population with a 
lower rate of colonization and protective effect of exposure on mechanism of harboring FQ-
susceptible pathogen does not exist.   
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CONTENT-BASED PROJECTS 
PROJECT-1 ABSTRACT 
BACKGROUND: Several studies have reported an increasing prevalence of high MIC-
fluoroquinolone susceptible E. coli (high MIC-FQSEC) which are the E. coli isolates with reduced 
susceptibility to FQ antibiotics. High MIC-FQSEC potentially results in development of fully FQ-
resistance and delayed response to FQ therapy. To date, risk factors for infection caused by high 
MIC-FQSEC have never been successfully identified. Our study aimed to identify risk factors for 
ambulatory urinary tract infections (UTIs) caused by high MIC-FQSEC in women. 
METHODS: We conducted a case-control study of female subjects with UTIs caused by FQSEC 
at outpatient services within University of Pennsylvania Health System, Philadelphia. Of subjects 
in whom FQSEC (a levofloxacin-MIC<4 mcg/mL) were isolated on urine culture, we included only 
those who met our study criteria of UTIs. Cases were subjects with UTIs caused by high MIC-
FQSEC (a levofloxacin-MIC≤0.12 mcg/mL) and controls were subjects with UTIs caused by low 
MIC-FQSEC, (a levofloxacin-MIC>0.12 but <4 mcg/mL). Cases and controls were compared with 
regard to demographics, comorbid conditions, and recent use of medications (particularly 
antibiotics) within the 90 days prior to the UTI onset. We obtained all necessary data from HUP 
clinical microbiology laboratory database and Penn data store. 
RESULTS: Two thousand  and one female subjects with FQSEC UTIs were included from May 1, 
2008 to April 30, 2011. A total of 91.8% had low MIC-FQSEC UTI while 8.2% had high MIC-
FQSEC UTI. Mean age was 56.9+/-22.6 years among cases and 57.3+/-22.0 years among 
controls. Approximately one-fourth of subjects in both groups had at least one underlying 
diseases. Independent risk factors for high MIC-FQ susceptibility included Asian race [95%CI: 
2.92; 1.29-6.58; p=0.02], having underlying renal diseases [95%CI: 2.18; 1.15-4.14; p=0.02]  and 
previous exposure to nitrofurantoin [95%CI: 8.86; 1.95-40.29; p=0.04].  
CONCLUSION: In addition to Asian race and having chronic renal diseases, recent use of 
nitrofurantoin was identified as an independent risk factor. Since this study was conducted among 
a relatively healthy population with a low prevalence of recent antibiotic use, we did not have 
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enough power to identify any associations between high MIC-FQSEC and other uncommonly 
used antibiotics. 
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PROJECT-2 ABSTRACT 
BACKGROUND: Negative impact of high MIC fluoroquinolone (FQ) susceptibility on treatment 
response to FQ antibiotics has been clearly documented in infections caused by Salmonella 
enterica serovar Typhi (S. typhi). However, no studies have successfully determined the impact of 
urinary tract infections (UTIs) caused by high MIC-fluoroquinolone E. coli (high MIC-FQSEC) on 
treatment efficacy of FQ therapy.    
METHODS: We conducted a retrospective cohort study of female subjects with FQSEC UTIs who 
received FQ therapy at outpatient services within University of Pennsylvania Health System, 
Philadelphia. In addition to retrieving data from the HUP clinical microbiology database and the 
Penn Data Store, we performed chart-review to capture all possible events of treatment failure. 
Exposed subjects were female subjects with high MIC-FQSEC UTIs while unexposed subjects 
were female subjects with low MIC-FQSEC UTIs.  
RESULTS: During the 3-year of study period, we enrolled 246 subjects into the low MIC group 
and 29 subjects into the high MIC group. Two of the 246 subjects in the low MIC group and two of 
the 29 subjects in the high MIC group experienced short-term treatment failure (0.8% vs. 6.9%, 
p=0.06). Risk difference and risk ratio for short-term treatment failure were 0.06 [-0.03-0.15; 
exact-p=0.06] and 8.48 [1.24-57.97; exact-p=0.06], respectively. By adjusting with the variable of 
underlying cerebrovascular diseases, the Odds Ratio (OR)  increased from 9.04 [95% CI=1.22-
66.77; p=0.03] to 9.73 [95% CI=1.11-85.16; p=0.04]. Including the variable of having at least one 
underlying disease into the final model reduced the OR of the high MIC-FQ susceptibility to 8.53 
[95% CI=1.14-63.96; p=0.04].  
CONCLUSION:  Our study was the first study demonstrating the negative impact of the high MIC-
FQ susceptibility on the treatment response to FQ therapy among female subjects with 
ambulatory UTIs caused by E. coli. We believe this negative impact may be more intensified in 
more serious clinical situations. Future studies in other clinical settings  should be conducted to fill 
the gap of knowledge. 
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BACKGROUND 
In recent decades, the emergence of antimicrobial resistance has become an important issue of 
clinical and public health concern. Since the widespread use of fluoroquinolones (FQs) in the late 
1990's, the prevalence of FQ resistance has been constantly increasing. Based on data from a 
U.S. study of outpatient urinary tract infections (UTIs), the prevalence of FQ resistance in E. coli 
urinary isolates was 1% in 1999 and subsequently increased to 9% in 2005.
1
 Furthermore, 
Canadian surveillance studies revealed that the prevalence of FQ resistance among outpatient E. 
coli urinary isolates increased from approximately 1% during the 2003-2004 period
2
  to 19% 
during the 2007- 2009 period.
3
 The increasing prevalence of FQ resistance has created very real 
challenges for physicians and healthcare institutions to treat these resistant infections as well as 
to implement effective interventions for controlling emergence of antimicrobial resistance.  
 The problem of emergence of FQ resistance among E. coli urinary isolates has important 
public health implications for several reasons. First, infections caused by resistant pathogens are 
associated with higher morbidity, higher mortality and increasing in hospital expenditures.
4-8
 
Second, E. coli is the most common causative pathogen of UTIs.
9
  Lastly, FQ antibiotics will lose 
their utility for treatment of UTIs if these trends in FQ resistance continue. Although considerable 
time and resources have been used to explore this problem, the gaps in knowledge still exist.   
Antimicrobial resistance as a global health threat 
The emergence of antimicrobial resistance has been recognized as a global health threat.
8
 
Acquiring a resistant pathogen does not only worsen clinical outcomes but also increases hospital 
expenditures.
4
 A cohort study of 662 hospitalized patients at a university hospital in the U.S. 
reported that hospital expenditures attributable to nosocomial infections caused by resistant 
gram-negative bacteria were 29.3% (95% CI=16.23-42.35; P<0.001) higher than nosocomial 
infections caused by antibiotic-susceptible gram-negative bacteria.
6
 In addition to higher antibiotic 
costs, an increase in overall hospital expenditures is also attributable to longer hospital stays, 
more laboratory and imaging tests as well as extra costs for rehabilitation services.
5-7
  
5 
 
 The limited number of effective antimicrobial agents in the market makes this situation even 
more critical. Due to this antibiotic pipeline crisis, the Infectious Diseases Society of America 
(IDSA) recently published the inaugural statement entitled "The 10x‘20 Initiative: Pursuing a 
Global Commitment to Develop 10 New Antibacterial Drugs by 2020". A global commitment to 
urgently develop new antibacterial agents is needed to resolve this critical situation. 
Fluoroquinolone (FQ) antibiotics and their properties  
The first quinolone, nalidixic acid first became available in the 1960s. The first generation-
quinolones were only active against gram-negative bacteria, not gram-positive bacteria.
10
 
Fluoroquinolones (FQs), the second generation-quinolones (norfloxacin, ciprofloxacin, 
lomefloxacin, ofloxacin and levofloxacin) were developed by adding a fluorine atom at position C-
6 of the quinolone molecule. This new molecular structure provided greater potency against 
gram-negative bacteria and moderate potency against gram-positive bacteria. The third 
generation-FQs (sparfloxacin, gatifloxacin and grepafloxacin) have higher potency against gram-
positive bacteria (especially pneumococci) while the fourth generation-FQs (trovafloxacin, 
moxifloxacin, gemifloxacin, garenoxacin and sitafloxacin) have expanded activity against common 
gram-positive bacteria and anaerobes.
11
 
  FQs have promising pharmacokinetic properties including excellent bioavailability and good 
tissue penetration. All FQ antibiotics on the market except moxifloxacin are mainly eliminated 
through the kidney and all are concentration-dependent antibiotics. The most important 
parameter predicting the efficacy of FQ therapy is the ratio of the area under plasma 
concentration-curve to minimal inhibitory concentration (AUC:MIC).
11
 Based on data from 
previous in-vitro and in-vivo studies
12-16
, the AUC: MIC threshold varies across organisms and 
sites of infection. A clinical trial of community-acquired respiratory tract infection caused by 
Streptococcus pneumoniae reported that an AUC:MIC ratio of 33.7 or higher is associated with a 
microbiological eradication rate of 100%.
14
 Furthermore, clinical studies evaluating the efficacy of 
ciprofloxacin for treatment of serious gram-negative bacterial infections found that the optimal 
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AUC: MIC ratio to achieve a maximum success rate and a shorter duration of bacterial 
eradication is ≥125.
13,15
 Given these findings, maximizing the AUC:MIC ratio should provide a 
better opportunity to cure infection and eradicate causative pathogens.
17
 
  FQ antibiotics were approved for treatment of a broad range of infections including urinary 
tract, respiratory, gastrointestinal, genital tract, bone and joint and systemic infections.
18,19
 
Because of their broad spectrum-coverage, favorable pharmacokinetic properties and promising 
clinical efficacy, the FQ antibiotics have been recommended as first-line therapy for 
uncomplicated cystitis and acute pyelonephritis in women since 1999.
20
 The substantial increase 
in FQ consumption has consequently led to emergence of FQ resistance.
21,22
  
Mechanisms of FQ resistance  
FQ antibiotics kill bacteria by binding to two enzymes (DNA gyrase and topoisomerase IV), 
resulting in disruption of the replication and transcription process of bacterial DNA.
10
 FQ 
resistance generally emerges by point mutations in the coding regions of the DNA gyrase 
subunits (gyrA and gyr B) and DNA topoisomerase IV (par C and par E) in a stepwise pattern.
23
 
As the number of mutations increases, the MIC to FQ increases. While DNA gyrase is the primary 
target in gram-negative bacteria
24
, topoisomerase is the primary target in most gram-positive 
bacteria.
25
 Data from several molecular studies revealed that E. coli urinary isolates with reduced 
susceptibility to FQs typically harbor a single mutation in a gyrA gene while E. coli isolates with 
full resistance to FQs (FQREC) usually have double mutations in the gyrA and parC genes.
26-28
  
These findings confirm that stepwise mutations are necessary for development of FQ resistance.   
 Other less common mechanisms of FQ resistance include alterations in membrane porin 
production and efflux pumps.
29
 Additionally, FQ resistance can be the result of the plasmid-
mediated multidrug-resistant qnr gene which can interfere with FQs from binding to bacterial 
DNA.
30,31
  
Minimal Inhibitory Concentration and FQ susceptibility interpretation  
The Minimum Inhibitory Concentration (MIC) is the lowest concentration of a given antibiotic that 
can inhibit growth of bacteria in vitro. The Clinical and Laboratory Standards Institute (CLSI) 
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develops the performance standards for antimicrobial susceptibility testing which have been 
widely used as the MIC interpretative standards in the United States and other countries 
worldwide.
32
 Antimicrobial susceptibility is traditionally reported as susceptible, intermediately 
susceptible, or resistant. The MIC-cutoff value (or MIC-breakpoint) of each antibiotic is chosen 
based on several factors including pharmacokinetics, pharmacodynamics and data obtained from 
previous clinical studies of that given antibiotic.   
 Several FQ antibiotics (such as ciprofloxacin, levofloxacin, ofloxacin, etc.) can be used as 
an indicator of FQ resistance. The MIC-cutoff value varies across the type of tested antibiotic and 
species of microorganism. For examples, an Enterobacteriaceae isolate is considered FQ-
susceptible (FQS) if the MIC to levofloxacin is < 4mcg/mL, FQ-intermediate susceptible (FQI) if 
the MIC to levofloxacin is ≥ 4 but <8 mcg/ml and FQ-resistant (FQR) if the MIC to levofloxacin is ≥ 
8 mcg/ml. Additionally, the MIC to ciprofloxacin of ≤1, 2 and ≥4 mcg/ml are used as a cutoff value 
to document FQS, FQI and FQR strains among Enterobacteriaceae isolates. 
  In addition to these three standard susceptibility groups (FQR, FQI and FQS), some 
investigators further categorized the FQS E. coli (FQSEC) into two additional groups, based on 
the MIC-cutoff value; 1) Low MIC-FQSEC group (MIC level to levofloxacin ≤0.25 mcg/mL); and 2) 
High MIC-FQSEC group (the MIC level to levofloxacin >0.25 but <4 mcg/ml). In some studies, 
these two groups were also called fully susceptible strains and reduced susceptible strains, 
respectively.
27,33
 This additional categorization is important because the high MIC-FQSEC is 
strongly associated with the presence of single mutation in the gyrA gene.
27
  
Epidemiology of infections caused by FQR and high MIC-FQS pathogen 
Only a few years after the introduction of FQs, emergence of FQ resistance was reported.
21,34
 
Since then, the prevalence of FQ resistance has been constantly increasing across bacterial 
organisms, sites of infection and geographical locations. Data from the 1997 SENTRY 
antimicrobial surveillance program revealed that the prevalence of FQ resistance among 
community-acquired and nosocomial bacteremia in the United States was 2.4% in E. coli, 1.6% in 
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Klebsiella spp. and 4.2% in Enterobacter spp.
35
 The 2008-2010 SENTRY study subsequently 
reported the higher prevalence of FQ resistance among gram-negative bacilli isolated from Latin 
American medical centers. The prevalence of FQ resistance in this study was 40.2% in E. coli, 
41.3% in Klebsiella spp. and 21.1% in Enterobacter spp group.
36
  Emergence of FQ resistance 
has been documented in the long-term-care facility (LTCF) setting as well. A 1998 - 2003 survey 
of 4,954 clinical isolates from four LTCFs in U.S. revealed that the prevalence of FQ resistance in 
Enterobacteriaceae organisms ranged from 7.8% to 48.7%.
37
 
 The problem of FQ resistance is even more critical among uropathogens.
1,33,38,39
 A U.S. 
study of outpatient UTIs reported that the prevalence of FQ resistance in E. coli urinary isolates 
was 1% in 1999 and subsequently increased to 9% in 2005.
1
 The increasing prevalence of FQ 
resistance among E. coli uropathogen was also documented in Canada. Based on data from 
recent surveillance studies from Canada, the prevalence of FQ resistance among outpatient E. 
coli urinary isolates increased from approximately 1% in 2003-2004
2
  to 19% in 2007- 2009.
3
  
Furthermore, a study of community-acquired UTIs conducted in Turkey revealed that 17% of E. 
coli strains isolated from uncomplicated cases and 38% of E. coli strains isolated from 
complicated UTI were resistant to FQ.
40
  
In addition to the high prevalence of FQ resistance, a significant proportion of high MIC-
FQSEC has been reported from several studies.
27,33
 A 1998 Taiwan nationwide survey of 1,203 
E. coli urinary isolates found that 11.3% of isolates were resistant to FQ and 21.7% of isolates 
were high MIC-FQS strains.
27
 Data from a surveillance of fecal E. coli isolates at two hospitals in 
U.S. revealed that the prevalence of FQR isolates and high MIC-FQS isolates were 12.9% 
(102/789) and 5.8% (46/789), respectively.
33
  
A number of studies in the past have investigated risk factors for FQ resistance across 
infecting organisms and sites of infection. A case-control study from U.S. community and 
university hospitals investigating nosocomial E. coli and K. pneumoniae infections, noted that FQ 
resistance was independently associated with recent FQ use (OR [95% CI] = 5.25 [1.81-15.26]), 
residence in a long-term care facility (3.65 [1.64-8.15]), recent aminoglycoside use (8.86 [1.71-
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45.99]) and older age (1.03 [1.01-1.06]).
38
 Another case-control study from a German university 
hospital compared 51 case patients with nosocomial FQREC infections to 102 control patients 
with nosocomial FQSEC infections. Independent risk factors for FQ resistance from this study 
were prior FQ therapy (OR [95% CI] =18.49 [5.53-61.82]), urinary tract abnormalities (6.69 [1.68-
26.63]) and prior therapy with other antimicrobial agents (3.57 [1.38-9.27]).
41
 During 1995-2002, a 
prospective cohort study of invasive pneumococcal infection was conducted to investigate 
epidemiology of antimicrobial resistance. This study found that infection with FQR pneumococci 
was significantly associated with previous FQ use (OR [95% CI] = 12.10 [4.22-35.40]), current 
residence in a nursing home (12.9 [3.95-43.9]) and nosocomial acquisition of pneumococcal 
infection (9.94 [2.22-44.60]).
42
 
Risk factors for FQ resistance in a specific site of infection such as UTI have also been 
investigated in many studies.
43-45
 A case-control study comparing 136 case patients with FQR 
gram-negative UTIs to 139 control patients with FQS gram-negative UTIs found a strong 
association between FQ resistance with several factors including recent exposure to beta-
lactamase inhibitors (OR [95% CI] =14.98 [2.92-76.99]), extended spectrum cephalosporins (9.82 
[3.37-28.60]), FQs (5.36 [2.20-13.05]) and clindamycin (13.90 [1.21-10.49]).
44
   A 2004 study of 
community-acquired UTIs revealed that UTIs caused by  FQREC were strongly associated with 
previous exposure to FQs (OR [95% CI] = 30.35 [5.82-158.42]) and recurrent UTIs (8.13 [2.95-
22.37]).
43
 Recently, a nested case-control study was conducted to assess risk factors for FQ 
resistance in community-onset febrile E. coli UTIs. This study documented recent exposure to FQ 
(OR [95% CI] =17.5 [6.0-50.7]) and recent hospitalization (2.0 [1.0-4.3]) as independent risk 
factors for FQ resistance.
45
 In summary, recent FQ exposure has been documented as an 
independent risk factor for FQ resistance across infecting organisms, sites of infection and study 
settings (community hospital, university hospital and ambulatory setting).
38,40,41,43-50
  
While a substantial number of studies focused on risk factors for infections caused by FQR 
pathogens, knowledge of risk factors for infections caused by high MIC-FQS pathogens is very 
limited. To our knowledge, the 1998 Taiwan-nationwide survey was the only study that 
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investigated risk factors for infection caused by high MIC-FQSEC.
27
 This study included 1,203 
clinical isolates of E. coli from all sites of infection, all age groups and both outpatient and 
inpatient settings. They subsequently compared characteristics of 19 patients with high MIC-
FQSEC infection to 57 patients with low MIC-FQSEC infection. This study did not detect any 
significant association between the high MIC-FQ susceptibility and patients' demographics, 
underlying diseases, length of hospitalization, presence of invasive catheter or recent exposure to 
antimicrobial therapy. This was most likely related to the very small sample size. Another 
important limitation of this study was the heterogeneity of study population. This study included 
isolates from all anatomic infection sites and both inpatient and outpatient settings while risk 
factors for high MIC-FQSEC infections may differ across anatomic sites and clinical settings.  
Thus far, the risk factors for infections caused by high MIC-FQSEC have never been successfully 
identified. 
Impact of FQ susceptibility on efficacy of FQ therapy 
Over the past decade, the prevalence of FQ resistance among uropathogens has been constantly 
increasing.
1,51
  Decrease in treatment efficacy of FQ therapy has been noted in several studies of 
E. coli UTIs.
52,53
  According to data from clinical studies conducted in late 80’s, short course FQ 
regimens for treatment of uncomplicated UTIs provided an approximately 95% clinical cure rate 
and 90% microbiological cure rate.
54-57
  In a recent clinical trial of uncomplicated UTI which was 
conducted in an area with a relatively high prevalence of FQREC (>10%), a 3-day norfloxacin 
regimen (400 mg twice a day for 3 days) achieved only a 76% complete response rate.
53
 In 
another recent study of uncomplicated UTIs, a short course gatifloxacin regimen (200 mg once 
daily for 3 days) provided only a 93% overall clinical cure rate (95% in susceptible cases and  
75% in resistant cases).
52
                                                                                     
Due to the increased prevalence of FQ resistance among uropathogens, the international 
clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in 
women was updated by the IDSA and the European Society of Microbiology and Infectious 
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Diseases (ECMID) in 2011.
58
 They recommend using alternative antimicrobials (such as 
nitrofurantoin or trimethoprim-sulfamethoxazole) for treatment of uncomplicated cystitis. FQ 
therapy should be reserved only for patients with acute pyelonephritis in areas in which the 
prevalence of FQ resistance is not known to exceed 10% (A-I). 
The negative impact of high MIC-FQ susceptibility on treatment outcomes has been 
previously documented in several studies. However, the majority of these studies specifically 
focused only on infections caused by Salmonella enterica serovar Typhi (S. typhi).
59,60
 An 
association between reduced susceptibility to ofloxacin and clinical outcome in patients with 
enteric fever who received ofloxacin has been clearly demonstrated in a recent publication from 
Vietnam.
59
  This study obtained individual patient data from 7 open randomized controlled trials of 
antibiotic therapy among subjects with enteric fever in Vietnam. A total of 540 subjects with 
enteric fever who were treated with ofloxacin were included while subjects who received other 
types of antibiotic were excluded. The treatment success rate among subjects with infection 
caused by high MIC-FQS S. Typhi (a MIC to ofloxacin 0.25-0.50 mg/L) was only 73% while the 
treatment success rate among subjects with infection caused by low MIC-FQS S. Typhi 
 (a MIC to ofloxacin ≤0.125 mg/L) was 96%. In addition to a lower treatment success rate, 
subjects with infection caused by high MIC-FQS S. Typhi were more likely to receive a higher 
dosage of ofloxacin and/or a longer duration of therapy.  
Furthermore, the delay in treatment response to FQ therapy was noted in a case series of 
patients with infection caused by high MIC-FQS S. Typhi and S. Paratyphi 
60
 Among 21 patients 
who were infected with S. Typhi or S. Paratyphi, seven of them (33%) were infected with high 
MIC-FQS strains (a MIC to ciprofloxacin 0.125–0.5 mg/L ). Of these 7 subjects with the high MIC-
FQS strain, 70% of them (5 /7) were initially treated with oral ciprofloxacin and 80% of subjects 
who received oral ciprofloxacin (4/5) subsequently required intravenous FQ therapy or switching 
to other parenteral antibiotics.  
To date, no studies have determined the association between high MIC-FQ susceptibility 
and treatment efficacy of FQs among subject with UTI caused by E. coli. According to the 
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concept of optimal AUC:MIC of FQ antibiotics, maximizing the AUC:MIC ratio offers  a better 
opportunity to cure infection and eradicate causative pathogens.
17
 Therefore, it is reasonable to 
believe that the FQ treatment failure might be higher among subjects with high MIC-FQSEC UTIs 
when comparing to those with low MIC-FQSEC UTIs. However, this assumption has never been 
sufficiently proved in any in-vivo or in-vitro study.  
Therefore, we conducted two separate studies to explore these issues. The first project was 
a case-control study aiming to investigate risk factors for ambulatory UTIs caused by high MIC-
FQSEC E. coli in women. The second project was a retrospective cohort study aiming to 
investigate the clinical impact of high MIC-FQSEC UTI on clinical outcomes. Study subjects of 
project-2 were all subjects from the project-1 who received FQ therapy. Since there is no 
standard definition for ambulatory UTIs, we conducted a pilot study to determine the appropriate 
study definition to identify UTIs before pursuing these two projects. Furthermore, the results from 
this pilot study could be used to accurately estimate an achievable sample size for our proposed 
projects.   
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PILOT STUDY 
1. RATIONALE OF THE PILOT STUDY 
To date, only a few definitions for UTIs have been widely accepted in biomedical research. The 
most well-known one is the surveillance definition for healthcare-associated UTIs established by 
the Centers for Disease Control and Prevention/National Healthcare Safety Network 
(CDC/NHSN). The first version of the CDC/NHSN definition was  introduced in 1988
61
 and then 
updated in 2008.
62
 The CDC/NHSN definition has been widely used in epidemiological research, 
however it was specifically designed to identify healthcare-associated UTIs not ambulatory UTIs.  
Details of this definition are shown in table 1. 
Another well-known definition was proposed by the IDSA in 1992.
63
 This definition can be 
used to identify UTI episodes in various clinical settings (ambulatory UTI, healthcare-associated 
UTI, etc.). However, this definition was exclusively developed to evaluate new antimicrobial 
agents in clinical studies. Therefore, the majority of its criteria are clinical based and not suitable 
for studies using an electronic database.  
 In 2010, Landers et al conducted a study evaluating the ICD-9 coding algorithm to detect 
UTI in electronic data at a 745-bed tertiary hospital in New York.
64
 They compared several 
computer-based decision rules including combinations of laboratory data (culture reports and 
urinalysis findings), patient clinical data (fever), and administrative data (ICD-9 codes). The ICD-9 
codes include; 599.0 (Urinary tract infection, site not specified); 590.x (Infection of kidney); 595.0 
(Acute cystitis); 597.x (Urethritis, not sexually transmitted diseases). The ICD-coding algorithm 
reached only 55.6% sensitivity and 93.9% specificity when compared to combinations of urine 
culture and symptom-based definition. In addition to the poor sensitivity, this coding algorithm 
was specifically designed to detect UTI in the inpatient setting. Therefore, the Landers’s algorithm 
is not suitable for our study.  
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 To our knowledge, a standard definition of UTIs in the ambulatory setting has never been 
proposed. Therefore, a well-designed study to identify a standard definition of ambulatory UTIs 
was needed.  Our pilot study had two specific aims;  
 1) To establish a study definition to identify UTIs in the ambulatory setting,  
 2) To accurately estimate an achievable sample size for our proposed projects.   
2. METHODS  
The pilot study was conducted during Feb 1-April 30, 2011. We obtained a list of ambulatory 
subjects with significant E. coli bacteriuria (>10
5
cfu/ml for female and >10
4
cfu/ml for male) from 
the clinical microbiology laboratory at the Hospital of University of Pennsylvania (HUP). This 
laboratory serves more than 70% of clinical practices within the University of Pennsylvania Health 
System. 
We randomly sampled 100 subjects (all women) with significant E. coli bacteriuria during the 
study period. All subjects’ medical records were obtained via the EPIC/Medview system. To 
evaluate the applicability of the CDC/NHSN definition (table 1) and the ICD-9 coding algorithm to 
ambulatory subjects with FQSEC bacteriuria, we applied these two definitions to data that we 
obtained from EPIC/Medview. The written diagnosis of UTI on patients' medical record was 
considered a gold standard.  
3. RESULTS 
During the 3-month study period, 1,357 subjects with significant E. coli bacteriuria were identified, 
1,006 (74.1%) subjects with low MIC-FQSEC bacteriuria, 90 (6.6%) subjects with high MIC-
FQSEC bacteriuria, 8 (0.6%) subjects with FQIEC bacteriuria and 253 (18.6%) subjects with 
FQREC bacteriuria. Among 1096 subjects with significant FQSEC bacteriuria, a total of 930 (84.9 
%) subjects were female. Subsequently, we randomly sampled 100 subjects from these female 
subjects with FQSEC bacteriuria (low and high MIC-FQSEC bacteriuria).   
Among the 100 subjects who were enrolled into our pilot study, 3 subjects came from 
practices that have not yet employed the EPIC/Medview system. Thus, only 97 subjects had 
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available electronic medical records on the EPIC/Medview database for review. Of these 97 
subjects with available medical records, 90 subjects had a written diagnosis of UTI on their 
electronic medical record.  Detail and Test characteristics of each criterion and the combined 
criteria are shown in the table 2.  
 By using the C.4 criteria (combination of SS, DX and LAB criteria), we were able to 
capture 79 subjects with UTI and only one subject without UTI was falsely identified as having 
UTI. This C.4 criterion provided us the best discrimination ability (sensitivity=87.8.0% and 
specificity=85.7%) when comparing to all other combined criteria.    
4. DISCUSSION 
Based on the study results, the C.4 criteria provided the best discrimination ability. If we apply 
the C.4 criteria to all female subjects with significant FQSEC bacteriuria on the list from the HUP 
microbiology laboratory database, it is estimated that approximately 70% of these subjects were 
diagnosed with FQSEC UTI.  
5. TABLES 
Table 1. The CDC/NHSN definition for healthcare-associated UTIs 
To be diagnosed of UTI, eligible subjects must meet both criterion 1 and criterion 2. 
Criterion 1 The subject has a positive urine culture >10
5
cfu/ml, with no more than two species of 
microorganisms 
Criterion 2 At least one of the following 
a) Dipstick test positive for leukocyte esterase and/or nitrate 
b) Pyuria (>10 white blood cells (wbc) /mm
3
 or > 3 wbc /high power field of unspun urine)  
c) Physician diagnosis of a urinary tract infection  
d) Physician institutes appropriate therapy for UTI within 2 days of the culture date.
20,58
  
Appropriate antibiotic regimens are shown below.  
 Fluoroquinolones 
 Nitrofurantoin 
 Sulfamethoxazole-trimethoprim 
 Fosfomycin 
 Beta-Lactam agents, including amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime 
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Table 2. Sensitivity and Specificity of each criterion and combined criteria for UTIs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria  Sensitivity Specificity 
A. CDC/NHSN definitions   
    A.1 At least one sign and symptom criteria (SS) 
 ICD-9 code of urgency 
 ICD-9 code of frequency 
 ICD-9 code of dysuria 
 ICD-9 code of suprapubic tenderness 
25.6% (23/90) 85.7% (6/7) 
    A.2 At least one laboratory criteria (LAB) 
 Dipstick test positive for leukocyte esterase 
 Pyuria (>10 wbc/mm3 or > 3 wbc/HPF of unspun urine) 
21.7% (20/90) 85.7% (6/7) 
   A.3 Physician institutes appropriate therapy for UTI within 2     
          days of the culture date (RX) 
58.9% (53/90) 85.7% (6/7) 
B. At least one ICD diagnosis code of UTIs (DX) 
 599.0   Urinary tract infection, site not specified 
 590.x   Infection of kidney 
 595.0   Acute cystitis 
 597.x   Urethritis, not sexually transmitted diseases 
66.7% (60/90) 100% (7/7) 
C. Combined criteria   
C.1 SS or LAB  40.0%(36/90) 85.7%(6/7) 
C.2 SS or DX 82.2%(74/90) 85.7%(6/7) 
C.3 LAB or DX 75.6% (68/90) 85.7%(6/7) 
C.4 SS or LAB or DX 87.8% (79/90) 85.7% (6/7) 
C.5 SS or LAB or DX or RX 94.4% (85/90) 71.4%(5/7) 
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PROJECT 1:  Risk factors for ambulatory urinary tract infections caused by                                
high MIC- fluoroquinolone susceptible E. coli in women 
1. METHODS 
We conducted a case-control study of female subjects with ambulatory UTIs caused by FQSEC 
from May 1, 2008 to April 30, 2011. The study was approved by the University of Pennsylvania 
Institutional Review Board.  
1.1 Study setting 
The study was conducted at outpatient practices within the University of Pennsylvania Health 
System (UPHS). The UPHS network consists of a broad range of healthcare facilities including 
one university hospital, two community hospitals, two specialty centers, six community practices 
and a number of outpatient clinical practices within the Clinical Care Associates (CCA) and within 
the Clinical Practices of the University of Pennsylvania (CPUP).  The CCA is a network of single 
and group primary care practices owned by UPHS as well as dozens of hospital and community 
based practices in both primary care and subspecialty medicine. CPUP is an integral part of Penn 
Medicine, with  a faculty practice plan and multispecialty satellite facilities providing over two 
million outpatient visits per year.   
 Since we identified eligible subjects through the database of the clinical microbiology 
laboratory at the Hospital of University of Pennsylvania (HUP), only practices that sent their 
clinical specimens for processing at the HUP microbiology laboratory during the study period 
were eligible for the study. Additionally, our major source of data was EPIC/MEDVIEW care (an 
electronic medical record system). Therefore only subjects from clinical practices that employed 
the EPIC/MEDVIEW system during the study period were eligible for the study.   
The UPHS network provides health services to the population who live within the greater 
Philadelphia area. Based on 2010 US census data, Philadelphia county has approximately 1.5 
million residents, in whom 47% are African-American, 42% White and 6.3% Asian. 
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1.2 Study subjects 
1) Adult female subjects (age ≥ 18 years) 
2) Had a positive urine culture for FQSEC (detail shown in the section 1.3.1)  
3) Met the study definition for UTIs (detail shown in the section 1.3.2) 
4) First episode of UTI during the study period (detail shown in the section 1.3.3) 
5) Registered to the UPHS system for at least 3 months prior to the index date 
1.3 Study definitions 
Subjects who met the following inclusion criteria were eligible for our study;  
1) Susceptibility to FQs
65
 
Microbiological tests were routinely processed at the clinical microbiology laboratory 
located at HUP.  All tests were processed by the Vitek-2 system, according to the 
performance standards for antimicrobial susceptibility testing established by Clinical and 
Laboratory Standards Institute (CLSI). Levofloxacin was used as an indicator of 
resistance to the FQ class of antibiotics. An isolate was considered FQ resistant (FQR) if 
the minimum inhibitory concentration (MIC) to levofloxacin was ≥ 8 mcg/ml. An isolate 
with MIC to levofloxacin < 4mcg/mL was considered FQ susceptible (FQS) while an 
isolate with an MIC to levofloxacin ≥ 4 but <8 mcg/ml was considered FQ intermediate 
susceptible (FQI). In addition, FQS urinary isolates were categorized into two groups; 1) 
high MIC-FQS, a FQS isolate with a MIC to levofloxacin ≤0.12; 2) low MIC-FQS, a FQS 
isolate with MIC to levofloxacin > 0.12 but < 4 mcg/mL. 
2) Index date: The date that a urine specimen with FQSEC was collected. 
3) Identification of subjects with E. coli UTI 
All potential study subjects for whom a urine culture grew E. coli were identified through 
the HUP clinical microbiology laboratory database. By using data retrieved from the 
EPIC/Medview database, only those who met our criteria for UTI within 7 days before or 
7 days after the index date were considered as having E. coli UTI. Since no standard 
definition for ambulatory UTIs has been established, we created our own study definition 
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by combining the CDC/NHSN surveillance definition of healthcare-associated UTIs and 
the ICD-9 coding algorithm to detect UTI in an electronic database based on our pilot 
study.
62,64
  Our study definition for UTIs is shown in table 3. Based on data from our pilot 
study, our study definition provided 87.8% sensitivity and 85.7% specificity to identify 
female subjects with E. coli UTI within our source population.  
4) Identification of subjects with the first episode of UTI 
 It is well known that a recurrent UTI is different from a new onset UTI in various aspects 
including risk factors, clinical course and outcomes.
66-68
 Therefore, we included only the 
first episode of UTI if a given patient had more than one episode of UTI during the study 
period. Subjects who had a UTI episode within 30 days prior to the beginning of the study 
were also excluded.  
 Furthermore, some subjects might have a UTI episode but did not have a 
positive urine culture due to several reasons (e.g. phone visit, no specimen collected, 
etc.). These UTI episodes were not captured by our study definition for UTIs and could 
lead to misclassifying a recurrent UTI as a new onset UTI. To reduce this problem, 
patients' data within 30 days prior to the index date was also reviewed. If at least one 
item of the criterion-2 was documented, that given episode of UTI was considered 
recurrent and removed from the study. 
5) Identification of cases and controls 
A subject in whom an E. coli urinary isolate was high MIC-FQS (the MIC to levofloxacin > 
0.25 but < 4 mcg/mL) was considered a case. A subject in whom an E. coli urinary 
isolate was low MIC-FQS (the MIC to levofloxacin ≤ 0.25 mcg/mL) was considered a 
control.  All eligible cases and controls were included without using any matching 
procedure.  
1.4 Data collection 
1) Data sources 
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We obtained all necessary data from two major sources: HUP clinical microbiology 
laboratory database, and Penn Data Store. The Penn Data Store is an internally 
developed virtual data warehouse which allows researchers to combine data from all key 
systems within UPHS. The list of key systems is shown below.  
a. EpicCare, an ambulatory electronic medical record (EMR) system which 
includes data from all outpatient practices within UPHS 
b. Sunrise, a Clinical Manager CPOE system and Sunrise Pharmacy (SRx) which 
includes inpatient order entry from all hospitals within UPHS 
c. Emtrac, an EMR system which includes data from all encounters at an 
Emergency Department 
d. Cerner Millennium Laboratory Information System, an updated laboratory 
database 
e. MedView, a web-based medical record aggregator 
The data elements provided by each source are summarized below (Table 4). 
2) Data to be collected 
Data on potential risk factors including age, race, clinic site and service (e.g., medicine, 
surgery), designated primary care provider, previous hospitalization, comorbid conditions, 
previous and current medications used and microbiological results were obtained from 
Penn data Store.   
 The presence of comorbid conditions was evaluated by applying the Enhanced 
ICD-9-CM coding algorithms to ICD-9 codes.
69,70
 Comorbid conditions included 
myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular diseases, dementia, chronic obstructive pulmonary disease (COPD), 
liver disease, diabetes mellitus (with or without complications), chronic renal disease, 
malignancy and HIV infection.  
 Outpatient and inpatient medications used within 90 days prior and after the 
index date were evaluated. We recorded data of the following medications including 
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antibiotics, steroids and other immunosuppressive agents. The antibiotic name, antibiotic 
category, as well as amount of antibiotic therapy were documented. Amount of antibiotic 
consumption was recorded in terms of the total number of antibiotic-days (defined as the 
sum of exposure to each antibiotic over the time period).  
 Our primary risk factor of interest was previous FQ exposure within the past 3 
months prior to the index date. Given that receiving FQ therapy prior to the time of culture 
can inhibit growth of FQ susceptible organisms, including very recent FQ therapy prior to 
the index date as the exposure may overestimate the risk effect of FQ antibiotic. 
Therefore, we excluded FQ antibiotics prescribed within 7 days prior to the index date to 
avoid overestimation of the effect of FQ exposure. Previous exposure to all other 
antibiotics was defined in the same way.  
 Urine culture results within 90 days prior and after the index date were also 
obtained. Obtained data included the date of obtaining specimen, the infecting organism, 
the number of isolated colony forming unit, the susceptibility profile as well as the minimal 
inhibitory concentration (MIC).  
3) Data verification 
If some study subjects may seek medical care at off-network sites, this may result in 
underestimation of previous antibiotic exposure. To assess for this possibility, we 
randomly selected a total of 200 of the eligible subjects for chart-review. Any encounters 
within 3 months before and after the index visit were reviewed to identify documentation 
of off-network visits (as noted in the Penn Medical Record). Of those subjects with 
documented  off- network visit, data on previous antibiotic exposure during that off-
network visit was obtained. We found that only three of the 200 subjects had at least one 
off-network visit within 3 months before or after the index date but all visits happened 
after the index date. Therefore, we believe that the off-network antibiotic therapy was 
minimal.   
4) Data Management 
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Data from all sources were stored in a computerized database management system. All 
information were kept strictly confidential.  All data were de-identified and coded with a 
unique identifier that is linked to his or her identity key before starting analysis. All 
electronic data were kept on a password protect computer while all paper documents 
were stored in a locked file cabinet at the study center. Only the principal investigator had 
an access to the identity key.    
 The HUP central microbiological laboratory and the Penn Data Store provided us 
the dataset from their existing data management system. These prevented errors that 
may occur while performing the data entry. All information from chart-review were 
recorded by using the data abstraction form. All entries were printed legibly in black ink. 
In case there is missing data, the explanations were added at the end of the abstraction 
form. Data entry was performed by the principal investigator. 
1.5 Statistical analysis  
1) Introduction 
First, we described the data distribution of each collected variable. Cases and controls 
were characterized by all potential risk factors including demographic variables, clinic site 
and service, comorbid conditions, previous medications used 3 months prior to the 
enrollment. Categorical variables were summarized by frequency while continuous 
variables were summarized by the mean, median, standard deviation, and range. For all 
calculations, a two-tailed P value of <0.05 was considered statistically significant.  All 
calculations were performed using the STATA version 12.0 (Stata Corp, College Station 
TX). 
2) Descriptive analysis 
We characterized case and control subjects by all characteristics including demographic 
variables, clinic site and service, comorbid conditions; previous medications used 3 
months prior to the enrollment. Categorical variables were summarized by frequency 
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while continuous variables were summarized by mean, median, standard deviation, and 
range as appropriate. 
3) Bivariable analysis 
Risk factors for high MIC-FQ susceptibility were thoroughly investigated by comparing 
characteristics of cases to controls. Our primary risk factor was previous exposure to FQ 
antibiotics within 3 months prior to the onset of infection.  Bivariable analysis was 
performed to determine the unadjusted association between all potential risk factors and 
high MIC-FQ susceptibility. Categorical variables were compared using the chi-square or 
Fisher’s exact test while continuous variables were compared using the student’s t or 
Mann-Whitney U test, depending on the sample distribution.  An unadjusted odds ratio 
(OR) and its confidence interval (CI) were reported. 
4) Stratified analysis 
Stratified analysis by Mantel-Haenszel test was subsequently performed to evaluate the 
effects of each variable of interest as a possible confounder as well as a possible 
interaction. The stratifying variables included year of enrollment, practice type (primary, 
secondary or tertiary care practices), previous hospitalization, age group, and presence 
of comorbid conditions. The presence of confounding was documented if a difference 
between the crude OR and the summary OR was more than 15%. Effect modification 
was assumed if the test for heterogeneity between the OR for different strata reached 
statistical significance (P<0.05).   
5) Multivariable analysis 
Multivariable analysis was performed by building an explanatory multiple logistic 
regression model. Forward-backward stepwise approach was used for selection of 
variables in the explanatory final model. Building of the multivariable model started with 
inclusion of our primary exposure variable (previous FQ exposure) regardless of its p-
value. Other variables were considered for inclusion in a multivariable model if their 
bivariable p-value < 0.20. In addition, we also included other variables if they were found 
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to a confounder on stratified analysis. These potential confounders were kept in the 
model if they changed the effect estimate of previous FQ exposure by 15% or more. 
Finally, we also investigated the possible presence of interaction between variables.  
6) Sample size and power calculation 
Based on preliminary data from the HUP clinical laboratory database, approximately 
2,700 low MIC-FQSEC and 300 high MIC-FQSEC urinary isolates were identified in 
2010. Data from our pilot study (as previously mentioned) revealed that approximately 
70% of these urinary isolates would be eligible for our study. Therefore, we anticipated 
that we would be able to enroll at least 5,600 cases and 560 controls to our study during 
3 years of study period. Details of sample size calculation is shown in table 5. We believe 
that it would be clinically meaningful to detect any risk factors with an odds ratio (OR) 
equal to 2.0 or more. By using an alpha=0.05, we would have ≥ 99% power to identify 
any clinically meaningful risk factors. Details of the power calculation are shown in table 
6.  
     Unfortunately, the exact sample size was remarkably lower than expected. We could 
enroll a total of 2,001 female subjects with non-recurrent FQSEC UTIs (165 subjects in 
the high MIC-group and 1,836 in the low MIC-group. However, based on this smaller 
sample size, we still had more than 80% power to detect any risk factors with an odd ratio 
(OR) equal to 2.0 or more if the baseline prevalence is >10% as shown in table 7.  
 
2. RESULTS 
During the 3-year study period, there were 11,287 urine specimens that grew E. coli >10
5
cfu/ml. 
Of these 11,287 urine specimens, approximately one-third of them (n=3,418) were obtained from 
subjects who met the definition for non-recurrent episode of UTI. Among those with non-recurrent 
episodes of E. coli UTI, seventy-eight percent were female (2,669 from 3,418).  When we focused 
only on non-recurrent episodes of E. coli UTI, 74.9% were in the FQSEC group, 0.4% in the 
FQIEC group and 24.7% in the FQREC group. Of these female subjects with FQSEC UTI 
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(n=2,001), a total of 91.8% (1,836/2,001) had low MIC-FQSEC UTI and 8.2% (164/2001) had 
high MIC-FQSEC UTI.   
     As mentioned previously, all female subjects with non-recurrent FQSEC UTI were enrolled into 
our study.  The female subjects with low MIC-FQSEC UTI were considered the cases (n=165) 
while the female subjects with high MIC-FQSEC UTI were considered the controls (n=1,836).   
Details of the susceptibility distribution are shown in table 8.    
     Demographics, diagnosis criteria for UTI and comorbid conditions of cases and controls are 
shown in table 9. Mean age and calendar year of enrollment were comparable between cases 
and controls. Asian race was significantly associated with high MIC-FQSEC in bivariable analysis 
[95%CI: 2.52; 1.25-5.07; p=0.02]. When comparing the diagnosis criteria for UTI between two 
groups, the ICD-9 code for UTI was significantly prevalent among cases [95%CI: 1.48; 1.02-2.19; 
p=0.03]. Regarding to the comorbid conditions, cases were more likely to have congestive heart 
failure [95%CI: 2.44; 1.29-4.34; p=0.001] and renal diseases [95%CI: 2.05; 1.00-3.93; p=0.02]. 
Furthermore, the high MIC group was borderline associated with having acute myocardial 
infarction [95%CI: 1.77; 0.66-4.05; p=0.16]. 
By comparing previous drug exposure between two groups, the high MIC group was more 
likely to be previously exposed to overall antibiotics [95%CI: 1.80; 0.67-4.12;p=0.15],  
nitrofurantoin specifically [95%CI: 5.65; 0.51-39.73; p=0.08] and H2 blocker agents [95% CI: 2.12; 
0.39-7.51; p=0.20]. However, these findings did not reach statistical significance in bivariable 
analysis. Details of previous drug exposure within 90 days prior to the index date are shown in 
table 10.  
The variables that remained independent risk factors for high MIC-FQSEC UTI after 
multivariable analysis are shown in 11.  Independent risk factors for high MIC-FQ susceptibility 
included Asian race [95%CI: 2.92; 1.29-6.58; p=0.02], having renal disease [95%CI: 2.18; 1.15-
4.14; p=0.02]  and previous exposure to nitrofurantoin [95%CI: 8.86; 1.95-40.29; p=0.04].  
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3. DISCUSSION 
Our study revealed that the distribution of FQ susceptibility is similar across clinical settings.  
Approximately one-fourth of isolates from subjects with E. coli bacteriuria, subjects with non-
recurrent episode of E. coli UTI and female subjects with non recurrent episode of E. coli UTI 
were resistant to FQs. The remaining three-fourth of isolates from these three subgroups were 
susceptible to FQs. Of these susceptible isolates, less than one percent were considered high 
MIC-FQSEC.  The prevalence of high MIC-FQSEC documented in our study was relatively low 
(6.1%) while the prevalence of FQREC was relatively high (24.7%) when compared to data from 
the Taiwan surveillance study of E. coli conducted in 1998
27
.  Unlike our study, the Taiwan study 
did not exclude colonization cases or recurrent cases.  Another important difference is the Taiwan 
study obtained clinical isolates of E. coli from both inpatient and outpatient settings.  
     One of the independent risk factors for high MIC-FQSEC UTI discovered in our study was 
Asian race. 
44
Racial disparity has been described in various infections caused by antibiotic-
resistant pathogens.
44,71,72
 For instance, a recent study conducted at University of Pennsylvania 
revealed that African-American race was an independent risk factor for healthcare-acquired UTIs 
caused by FQR gram-negative bacilli.
44
 However, the association between Asian race and 
antibiotic resistance has never been documented. It is unclear how to explain this observed 
relationship. We hypothesize that this may be the result of differences in amount of antibiotic 
consumption, pharmacokinetic/pharmacodynamics of antibiotics, or dietary patterns. It is well 
known that exposure to a subtherapeutic level of antibiotic is associated emergence of antibiotic 
resistance.
73,74
  Because Asian people tend to have a smaller body size, elimination of an 
antibiotic may take time longer and lead to prolonged exposure to subtherapeutic level of 
antibiotic.  In addition to direct exposure of antibiotic, antibiotic use in food production is also an 
important source of non-therapeutic antibiotic exposure. Given that antibiotic use in agriculture 
and livestock can result in emergence of antibiotic resistance
75,76
, it is reasonable to believe that 
some dietary patterns may be a risk factor for acquiring antibiotic-resistant pathogens.  However, 
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we could not explain why this specifically affects only Asian subjects, therefore further study 
exploring the racial differences should be performed.  
     Renal disease was also identified as an independent risk factor for high MIC-FQSEC UTI.  
The correlation between the renal disease and several types of antibiotic resistance has already 
been documented
77-79
.  In addition, it is well-known that patients with renal diseases are more 
likely to receive antibiotics especially urinary anti-infective agents.    
     Nitrofurantoin was found to be an independent risk factor for high MIC-FQSEC UTI.. Given 
that the only approved indication of nitrofurantoin is for the treatment of acute uncomplicated UTI 
(acute cystitis) caused by susceptible strains of E. coli or Staphylococcus saprophyticus, we 
hypothesized that subjects without E. coli bacteriuria but with signs and symptoms of UTI may be 
treated with nitrofurantoin. SImilarly, subjects with E. coli bacteriuria but had no sign and 
symptom of UTI may be treated with nitrofurantoin as well. To evaluate this hypothesis, we further 
extracted data from electronic medical records of all study subjects who were previously exposed 
to nitrofurantoin (n=6). Of these six subjects who had history of previous nitrofurantoin exposure 
(n=4 in the low MIC group and n=2 in the high MIC group), three in the low MIC group and none 
in the high MIC group had at least one episode of E. coli bacteriuria prior to the index date. 
However, these 3 subjects did not meet our study definition for UTIs and would thus not have 
been excluded based on a possible recurrent UTI Given our approach to identification of eligible 
study subjects (based on a positive urine culture) it is impossible to know how many subjects with 
sign and symptom of UTI were treated with nitrofurantoin without documented E. coli bacteriuria.     
Surprisingly, we could not detect any significant association between high MIC-FQSEC UTI 
and other antibiotics except nitrofurantoin. Since we enrolled all study subjects from the 
ambulatory setting, the majority of them had no comorbidities and no history of previous antibiotic 
exposure. Given this very low prevalence of antibiotic exposure among our study subjects, a 
small association may be missed.  We also tested a new capture period for previous antibiotic 
exposure to see whether the prevalence of previous antibiotic exposure would differ. As noted 
previously, excluded antibiotic use in the 7 days prior to the UTI from consideration as a risk 
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factor (assuming this antibiotic use reflected early therapy for the UTI that would be identified 
shortly). In a secondary analysis, we changed this exclusion period to 3 days, rather than 7 days. 
However, the previous antibiotic exposure was unchanged.  
 Our study has numerous strengths. To our knowledge, this was the first study which was 
specifically designed to investigate risk factors for ambulatory UTIs caused by high MIC-FQSEC. 
Since risk factors for developing high-MIC susceptibility might be different across sites of 
infection, causative organisms and clinical settings (inpatient, outpatient or long-term care 
facility), therefore our study focused exclusively on ambulatory UTI caused by FQSEC in women. 
We also excluded all recurrent episodes of UTIs because they may be different from non-
recurrent UTIs.  Unlike the previous study that failed to distinguish true infection from 
colonization
27
, our study enrolled only subjects with documented FQSEC-UTI. Furthermore, we 
carefully performed a pilot study to select the most accurate diagnosis criteria for ambulatory 
UTIs because the standard definition for UTIs in the ambulatory setting has never been 
established. 
 Our large study sample size is considered the strength as well. Even our study had the 
smaller-than-expected sample size but it was still the largest study that primarily focused on high 
MIC-FQSEC UTI.  Based on a total sample size of 2,001 subjects (165 cases vs. 1,836 controls), 
we had more than 80% power to detect any risk factors with an OR of 2 or more if the exposure 
prevalence in the control group ranges between 0.1 to 0.9. Therefore, we believe that our study 
had an adequate power to identify any clinically meaningful risk factors for high MIC- FQEC UTIs.   
 Our study also has some potential limitations. A major concern in a case-control study is 
selection bias. Selection bias occurs when a probability of being selected to be either the case or 
the control is related to some specific factors other than having the disease. Since our study 
definition of UTI mainly relied on urine culture results, combined with data from the Penn Data 
Store and the HUP microbiology laboratory database, this might be a source of selection bias. To 
minimize this problem, we also performed the pilot study to identify the most accurate diagnosis 
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criteria for ambulatory UTIs. We used the diagnosis criteria that have been shown to provide 
good discrimination ability (sensitivity=87.8% and specificity=85.7%).  
Although we used the validated criteria to identify subjects with FQSEC UTIs, the potential for 
selection bias still exists. For example, urine examination and urine culture are more likely to be 
requested in subjects with previous history of UTI. Furthermore, some patients with UTI may not 
seek medical attention or their attending physician does not request urine culture. Therefore, 
sicker patients are more likely to be diagnosed UTI by our study definition.  However, there is no 
reason to believe that this bias would be differential between cases and controls.  
Another potential limitation in nearly all case-control studies is misclassification bias. 
Although the case or control status was unlikely to be misclassified, the exposure may be 
underestimated. Since the exposure of interest was only obtained through the Penn Data Store, 
we could not capture any antibiotic prescriptions outside UPHS. To evaluate the magnitude of this 
issue (as described previously), we randomly selected 200 subjects and performed chart-review 
to evaluate how many subjects had a history of an off-network visit. Of these 200 subjects, only 3 
of them (1.5%) had at least one off-network visit within 3 months before or after the index date. 
However, these three off-network visits all happened after the index date. Therefore, we believe 
that the off-network antibiotic therapy prior to the index date should be very minimal.   
Another potential limitation is missing data.  This is a common problem when conducting a 
study using information from the electronic medical record database. Since the Penn Data Store 
was not specifically designed for research purpose, some important variables may be 
unavailable. Additionally, completeness of data depends on patients' physicians and other related 
personnel.  To ameliorate this problem, we carefully reviewed the infra-structure of Penn-data 
store and our study protocol to utilize all available information. We also performed a pilot study to 
validate the criteria for diagnosis of FQSEC UTI as previously mentioned. 
The last potential limitation is generalizability. Our study population was drawn from a number 
of ambulatory practices within the UPHS; therefore it is possible that results of this study may not 
be applicable to populations in other settings or other geographic regions. To explore this issue, 
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we subsequently performed additional analysis on different groups of the population including 1) 
all subjects with FQSEC-bacteriuria (either true infection or colonization) and 2) both female and 
male subjects with non-recurrent FQSEC-UTIs. Independent risk factors identified in the 
bacteriuria model (902 cases and 5,483 controls) included Asian race [95%CI: 2.33; 1.41-3.81; 
p=0.001], race rather than black and white [95%CI: 1.65; 1.15-2.37; p=0.007] and underlying 
heart failure [95%CI: 2.58; 1.67-3.98; p<0.001]. Results from the both sex model (213 cases and 
2,233 controls) revealed that Asian race [95%CI: 3.07; 1.48-6.37; p=0.003], underlying heart 
failure [95%CI: 2.21; 1.35-3.62; p=0.002] and previous exposure to nitrofurantoin [95%CI: 8.42; 
1.86-38.11; p=0.006] were independently associated with high MIC-FQSEC UTIs. Although 
results from these three models (non-recurrent FQSEC-UTIs in female, asymptomatic FQSEC 
bacteriuria and non-recurrent FQSEC-UTIs in both sex) are similar, these results may be different 
in other clinical settings such as nosocomial UTIs, sicker populations, etc.   
In conclusion, our study was the largest study specifically designed to identify risk factors for 
high MIC-FQSEC UTI. Our study revealed three independent risk factors including Asian race, 
underlying renal disease and previous exposure to nitrofurantoin. Data from chart-review 
confirmed that previous exposure to nitrofurantoin was a likely a proxy for prior UTI episodes that 
did not meet our study definitions for UTIs. Further studies are needed to explore the association 
between Asian race and high MIC-FQSEC UTIs.  
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4. TABLES 
Table 3. Definition of urinary tract infections (UTIs) 
To be diagnosed of UTI, the eligible subjects must meet both criterion 1 and criterion 2. 
Criterion 1 Patient has a positive urine culture >10
5
cfu/ml, with no more than two species of 
microorganisms 
Criterion 2 At least one of the following 
a) ICD -9 code of signs and symptoms of UTIs  
b) Dipstick test positive for leukocyte esterase and/or nitrate 
c) Pyuria (>10 white blood cells (wbc) /mm
3
 or > 3 wbc /high power field of unspun urine)  
d) Physician diagnosis of a urinary tract infection (ICD-9 code) 
 599.0 Urinary tract infection, site not specified 
 590.x Infection of kidney 
 595.0  Acute cystitis 
 597.x Urethritis, not sexually transmitted diseases 
Table 4. Sources for data collection 
Data Microbiology lab database Penn Data Store 
Study eligibility      
Microbiological results and susceptibility profile    
Clinic site and services    
Baseline demographic data    
Co-morbidities    
Previous hospitalization    
Medications used      
Treatment outcomes (for the cohort study)    
 
Table 5. Sample size calculation  
 
Susceptibility  No. of isolates  
in 2010 
Estimated number of 
isolates during the 3-
year study period 
Expected samples size 
during  
the 3-year study period 
Low MIC- FQSEC Isolates 2684 8000 5600 
High MIC-FQSEC Isolates 273 800 560 
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Table 6. Power calculation for the expected sample size 
 
Table 7. Power calculation for the exact sample size 
 
Table 8.  Distribution of FQ susceptibility among subjects with E. coli bacteriuria, non-recurrent E. 
coli UTI episodes and female subjects with non-recurrent E. coli UTI  
Susceptibility  E. coli bacteriuria 
Non-recurrent episode of E. 
coli UTI  
Adult Female with a non-
recurrent episode of  E. coli UTI 
All 11,287 (100.0%) 3,418 (100%) 2,669 (100%) 
1. FQSEC 8,461 (75.0%) 2,464 (72.1%) 2,001 (74.9%) 
 Low MIC  7,967 (68.8%) 2,252 (65.9%) 1,836 (68.8%) 
 High MIC  740 (6.4%) 212 (6.2%) 165 (6.1%) 
2. FQIEC 49 (0.4%) 12 (0.4%) 11 (0.4%) 
3. FQREC 2,777 (24.6%) 942 (27.6%) 658 (24.7%) 
  
Prevalence of exposure  
in the control group  
Prevalence of UTIs = 70% Among the source population 
(560 cases:5600 controls) 
OR = 1.25 OR = 1.5 OR = 2.0 
.10  0.36 0.82 0.99 
.20  0.54 0.97 0.99 
.30  0.65 0.99 0.99 
.40  0.70 0.99 0.99 
.50  0.71 0.99 0.99 
Prevalence of exposure 
in the control group  
Sample size = 2,001 subjects (165 cases and 1,836 controls) 
OR = 1.5 OR = 2.0 OR = 3.0 
.10  0.36 0.82 0.99 
.20  0.55 0.97 0.99 
.30  0.64 0.98 0.99 
.40  0.68 0.99 0.99 
.50  0.67 0.99 0.99 
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Table 9. Demographics, diagnosis criteria for UTI and comorbidity among the cases and controls. 
Variables High MIC (N=165) Low MIC 
(N=1,836) 
Unadjusted Odds 
Ratio (95% CI) 
p-value 
N % N % 
Demographics 
Age (Mean+/-SD) 56.91±22.57 57.34±21.98 0.99 [0.99-1.00] 0.81 
Year of enrollment      
 
 
0.51 
 2008 49 29.9 487 26.5 Ref 
 2009 62 37.8 750 40.9 0.96 [0.68-1.36] 
 2010 36 22 450 24.5 0.92 [0.62-1.36] 
 2011 17 10.4 149 8.1 1.28 [0.76-2.15] 
Race       
 White 64 39.0 766 41.7 Ref 
0.02 
 Black 77 47.0 931 50.8 1.00 [0.71-1.41] 
 Asian 8 4.9 34 1.9 2.82 [1.25-6.34] 
 Other/Unknown 15 9.1 105 5.7 1.71 [0.94-3.11] 
Diagnosis Criteria for UTI 
Diagnosis by ICD-9 123 75 1250 68.0 1.41 [0.97-2.08] 0.07 
 Sign and Symptom of UTI 5 3 61 3.3 0.92 [0.28-2.30] 0.85 
 Pyuria 0 0 0 0 - - 
 Diagnosis code of UTI 123 75 1227 66.9 1.48 [1.02-2.19] 0.03 
 UTI in pregnancy 36 22 400 21.8 1.01 [0.67-1.50] 0.95 
Diagnosis by laboratory 
results 
84 51.2 1016 55.3 
0.85 [0.61-1.19] 
0.32 
 Microscopic pyuria 83 50.6 1003 54.6 0.85 [0.61-1.19] 0.32 
 Positive urine leukocyte 
esterase test 
61 37.2 746 40.6 
0.87 [0.61-1.22] 
0.39 
 Positive urine nitrite 35 21.3 508 27.7 0.71 [0.47-1.05] 0.08 
Co-morbidity 
 Charlson index (mean+/-SD) 0.45 0.79 0.4 0.72  0.35 
 Having at least one 45 27.4 476 25.9 1.08 [0.74-1.56] 0.67 
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Charlson conditions 
 Acute Myocardial Infarction 7 4.3 45 2.5 1.77 [0.66-4.05] 0.16 
 Congestive Heart Failure 16 9.8 78 4.3 2.44 [1.29-4.34] 0.001 
 Peripheral Vascular Disease 4 2.4 48 2.6 0.98 [0.24-2.59] 0.57* 
 Cerebrovascular disease 12 7.3 131 7.1 1.03 [0.51-1.91] 0.93 
 Dementia 1 0.6 8 0.4 1.40 [0.03-10.56] 0.54* 
 COPD 6 3.7 86 4.7 0.77 [0.27-1.79] 0.55 
 Rheumatoid disease 2 1.2 12 0.7 1.88 [0.20-8.54] 0.32* 
 Peptic Ulcer 2 1.2 10 0.5 2.25 [0.24-10.70] 0.26* 
 Mild Liver Disease 1 0.6 13 0.7 0.86 [0.02-5.80] 0.99* 
 Moderate/Severe Liver 
disease 
0 0 
6 0.3 - 
0.99* 
 All diabetes 5 3.0 36 2.0 1.57 [0.47-4.10] 0.38 
 Diabetes without 
complication 
2 1.2 
23 1.3 0.97 [0.11-4.00] 
0.66* 
 Diabetes with complication 4 2.4 17 0.9 2.68 [0.65-8.33] 0.09* 
 Hemiplegia or Paraplegia 2 1.2 13 0.7 1.73 [0.19-7.75] 0.35* 
 Renal disease 12 7.3 68 3.7 2.05 [1.00-3.93] 0.02 
 Cancer 8 4.9 134 7.3 0.65 {0.27-1.35] 0.25 
 Metastatic cancer 4 2.4 37 2 1.22 [0.31-3.45] 0.57* 
 AIDS 0 0 0 0 - - 
Note: * p-value from the non-parametric test 
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Table 10.   Recent drug exposure within 90 days  prior to the index date  
Medication High MIC 
(N=164) 
Low MIC 
(N=1,836) 
Unadjusted Odds 
Ratio (95% CI) 
p-value 
N % N % 
 All antibiotics 7 3.7 44 2.3 1.80 [0.67-4.12] 0.15 
 Bactrim 1 0.6 5 0.3 2.25 [0.05-20.24] 0.40* 
 Clindamycin 0 0 3 0.2 - 0.99* 
 Linezolid 1 0.6 0 0 -  0.99* 
 Metronidazole 0 0 6 0.3 - 0.99* 
 Nitrofurantoin 2 1.2 4 0.2 5.65 [0.51-39.73] 0.08* 
 Vancomycin 0 0 1 0.1 - 0.99* 
 Cephalosporins 0 0 5 0.3 - 0.99* 
 Fluoroquinolones 0 0 5 0.3 - 0.99* 
 Aminoglycoside 0 0 0 0 - - 
 Penicillin 2 1.2 10 0.5 2.25 [0.24-10.70] 0.26* 
 Beta-lactams 2 1.2 15 0.8 1.50 [0.16-6.53] 0.64 
 Macrolide 0 0 2 0.1 - 0.99* 
 Proton pump inhibitors 
 (D0 to D90) 
3 1.8 56 3.1  0.59 [0.11-1.86] 0.48 
 H2blocker (D0 to D90) 3 1.8 16  0.8 2.12 [0.39-7.51] 0.20 
Note: * p-value from the non-parametric test 
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Table 11. Independent risk factors for High MIC-FQSEC UTI (multivariable analysis) 
High MIC-FQSEC UTI Unadjusted OR [95% CI] Adjusted OR [95% CI] P-value 
 Race    
 
0.02 
 White Ref Ref 
 Black 1.00 [0.71-1.41] 0.99 [0.70-1.39] 
 Asian  2.82 [1.25-6.34] 2.92 [1.29-6.58] 
 Others 1.71 [0.94-3.11] 1.72 [0.94-3.15] 
Renal diseases 2.05 [0.99-3.93] 2.18 [1.15-4.14] 0.02 
Previous exposure to Nitrofurantoin 5.65 [0.51-39.73] 8.86 [1.95-40.29] 0.005 
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PROJECT 2: CLINICAL IMPACT OF AMBULATORY URINARY TRACT INFECTIONS 
CAUSED BY HIGH MIC- FLUOROQUINOLONE SUSCEPTIBLE E. COLI IN WOMEN 
 
1. METHODS 
This study was nested within the case-control study (project-1). We conducted a retrospective 
cohort study to compare treatment response to FQ therapy between subjects with low MIC-
FQSEC UTI and subjects with high MIC-FQSEC UTI. The study was approved by the Penn 
Institutional Review Board.  
1.1 Study setting 
Our study population was a subset of the case-control (the project-1) population. Same as the 
case-control study, the study was conducted at outpatient services within University of 
Pennsylvania Health System (UPHS), Philadelphia during May 1, 2008 – April 30, 2011.    
1.2 Study subjects 
Eligible subjects were those from the case-control study who received any FQ antibiotics as the 
first antibiotic regimen for UTI within 72 hours before or after an index urine culture was obtained. 
Subjects who did not receive any antibiotics within this capture period or received non-FQ 
antibiotic as the first course of antibiotic were excluded.    
 All subjects with high MIC-FQSEC UTI were enrolled into the exposed group while all 
subjects with low-MIC FQSEC UTI were enrolled into the unexposed group. 
1.3 Study definitions and outcomes of interest 
1) Susceptibility to FQ (as previously mentioned in the project-1) 
2) Index date: The date that the first course of FQ therapy was initiated. 
3) Short-term treatment failure: defined as any evidence of treatment failure 
documented between Day4 to Day14 after the index date.   
4) Long-term treatment failure: defined as any evidence of treatment failure 
documented between Day15 to Week10 after the index date.   
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5) Evidence of treatment failure: A given subjects was documented as having 
treatment failure if at least one of the following criteria were true within the captured 
period. 
 The second course of antibiotic therapy for UTI was prescribed  
 There was any evidence of persistent or recurrent E. coli bacteriuria (At least 103 
CFU/ml of E. coli)      
1.4 Data collection 
1) Data source: In addition to retrieving data from the HUP clinical microbiology 
database and the Penn Data Store, we additionally performed chart-review on the 
Epic and Medview systems to capture all possible events of treatment failure.   
2) Data to be collected: All variables previously collected in the case-control study 
were also collected and considered potential confounders and effect modifiers in this 
study.  
 Data on age, race, clinic site and service (e.g., medicine, surgery), designated 
primary care provider, previous hospitalization, comorbid conditions, previous and 
current medications used and microbiological results were obtained via the Penn 
data store. Microbiological data were obtained via the HUP clinical microbiology 
database. Treatment outcomes were obtained by performing chart-review. 
 The presence of comorbid conditions was evaluated by applying the Enhanced 
ICD-9-CM coding algorithms to ICD-9 codes.
69,70
 The comorbid conditions included 
myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular diseases, dementia, chronic obstructive pulmonary disease (COPD), 
liver disease, diabetes mellitus (with or without complications), chronic renal disease, 
malignancy and HIV infection.  
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 Outpatient and inpatient medications used within 90 days prior and after the 
index date were evaluated. We recorded data of the following medications including 
antibiotics, steroid and other immunosuppressive agents.   
 Urine culture results within 90 days prior and after the index date were also 
obtained. Obtained data included the date of obtaining specimen, the infecting 
organism, the number of isolated colony forming unit, the susceptibility profile as well 
as the minimal inhibitory concentration (MIC).  
3) Data management: This study used the same data management system as in the 
case-control study. 
1.5 Statistical analysis  
1) Introduction 
       Outcomes of interest included short-term treatment failure and long-term treatment 
failure while the exposure of interest was high MIC-FQ- susceptibility. Short-term and 
long-term outcomes were separately analyzed. The primary aim of this study was to 
determine the association between the high MIC-FQ susceptibility and treatment 
outcomes among subjects with ambulatory FQSEC UTI who received FQ therapy. 
Specific treatment outcomes evaluated included:  
1) Composite treatment failure: defined as presence of at least 1 criterion of 
treatment failure (presence or absence) 
2) Specific criteria for treatment failure as a dummy variable    
 Requirement of second course of antibiotic therapy,  
 Recurrent or persistent bacteriuria 
For all calculations, a two-tailed P value of <0.05 was considered statistically 
significant.  All calculations were performed using the STATA version 12.0 (Stata Corp, 
College Station TX). 
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2) Descriptive analysis 
We described the data distribution of each collected variable and then characterized the 
exposed and unexposed groups by all characteristics including demographic variables, 
clinic site and service, comorbid conditions, previous medications used 3 months prior to 
the enrollment, type and duration of FQ therapy and treatment outcomes. Categorical 
variables were summarized by frequency while continuous variables were summarized 
by the mean, median, standard deviation, and range as appropriate. 
3) Bivariable analysis 
Characteristics and outcomes of the exposed group and the unexposed group were 
compared.   Bivariable analysis was subsequently performed to determine the unadjusted 
association between the high MIC-FQ susceptibility and all variables. Furthermore, we 
also compared characteristics between subjects who experienced treatment failure and 
subjects who did not experience treatment failure to determine the unadjusted 
association between the treatment failure and all variables.  
     Categorical variables were compared using the chi-square or Fisher’s exact test while 
continuous variables were compared using the student’s t or Mann-Whitney U test, 
depending on the sample distribution.  An odds ratio (OR) and its confidence interval (CI) 
were then reported. 
4) Stratified analysis 
Stratified analysis by Mantel-Haenszel test was subsequently performed to evaluate the 
effects of each variable of interest as a possible confounder as well as a possible 
interaction. The stratifying variables included year of enrollment, previous hospitalization, 
clinic site and service, age group, presence of comorbid conditions, type of FQ therapy 
(e.g. norfloxacin, ciprofloxacin, levofloxacin, etc) and duration of FQ therapy (≤ 3 days vs. 
>3 days). We determined whether these factors alter the association between exposure 
and the outcomes. The presence of confounding was documented if the difference 
between the crude effect estimate and the summary effect estimate was more than 15%. 
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Effect modification was assumed if the test for heterogeneity between the OR for different 
strata reaches statistical significance (P<0.05).    
5) Multivariable analysis 
Multivariable analysis was subsequently performed by using a multiple logistic regression 
model.   Building of the multivariable model started with inclusion of our primary exposure 
variable (high MIC-FQ susceptibility). Other variables were considered for inclusion in a 
multivariable model if their bivariable p-value < 0.20 or they were found to be either 
confounder or interaction on stratified analysis. Forward-backward stepwise approach 
was used for selection of variables in the final model regardless of their p values. Finally, 
we also investigated the possible presence of interaction between variables. 
6) Secondary analysis 
a. Sensitivity analysis of MIC cut-off value  
Because there is no standard MIC value to distinguish the low MIC-FQSEC from the 
high MIC FQSEC, we additionally performed the sensitivity analysis by changing the 
MIC-cutoff value for determining high vs. low MIC-FQ susceptibility.  In this sensitivity 
analysis, an isolate with the MIC to levofloxacin ≤ 0.25 was considered low MIC-
FQSEC while and isolate with the MIC to levofloxacin >0.25 but <4 was considered 
high MIC-FQSEC. The analysis methods used in this secondary analysis were 
exactly the same as those previously mentioned in the primary analysis. 
b. Sensitivity analysis on outcome misclassification 
Given the fact that we may underestimate the number of treatment failures, therefore 
the effect of high MIC-FQ susceptibility may be wrongly estimated. To explore this 
issue, we performed the sensitivity analysis on both patterns (differential and non-
differential) and various degree of misclassification.    
7) Sample size and power calculation 
Only subjects from the case-control study who received FQ therapy were eligible for this 
study. Our expected prevalence of FQ therapy as the first antibiotic regimen was 80% 
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during May 2008-October 2010 (before the change in the IDSA guideline) and 20% 
during November 2010-April 2011 (after the change in the IDSA guideline). Given these 
numbers, we anticipated to enroll approximately 390 subjects in the exposed group and 
3900 subjects in the unexposed group. 
 A previous clinical study reported that the long-term treatment failure in FQSEC-
UTI patients who received a short course FQ therapy was 5%.
56
 Therefore, we expected 
that the short-term treatment failure in our study population must be > 5%.  Power 
calculations were performed by assuming that the prevalence of short-term treatment and 
long-term treatment failure among the unexposed group were 1% and 5%, respectively. 
Therefore, our study would have 99% and 95% power to detect at least 5% difference in 
the short-term and the long-term treatment failure, respectively. Detail of power 
calculation is shown in table 12.  
 Unfortunately, we were able enroll only 275 subjects into our cohort study (29 
subjects into the exposed group and 246 subjects into the unexposed group).  Based on 
this number, we still had more than 80% power to detect a difference in treatment 
response of 20% or more and the baseline treatment response is between 1-5% as 
shown in table 13.  Since we believe that clinically significant difference in treatment 
failure is 20% or more, our study did have enough power to detect the clinically significant 
difference.  
 
2. RESULTS 
During a 3-year study period, a total of 279 eligible subjects were identified through the Penn 
Data Store (248 subjects in the low MIC group and 31 subjects in the high MIC group). Of these 
279 eligible subjects, only 275 subjects had available medical records for review. Therefore, we 
finally enrolled 246 subjects into the low MIC group and 29 subjects into the high MIC group.      
 Median age (range) of the low MIC group and the high MIC group were 55 (18-99) years and 
64 (18-89) years, respectively. Baseline characteristics between these two groups did not show 
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statistically significant differences in the bivariable analysis. Baseline characteristics between the 
high MIC vs. low MIC group are shown in table 14.  
     Two of the 246 subjects in the low MIC group and two of the 29 subjects in the high MIC group 
experienced short-term treatment failure (0.8% vs. 6.9%, p=0.06). Of these four subjects with 
short-term treatment failure, all of them had persistent signs or symptoms of UTIs and 
subsequently required the second course of antibiotic therapy.  However, only one from four had 
a repeated urine culture, which later grew no pathogen. No long-term treatment failure was 
detected among our study population.  Detail of treatment failure or each subject is shown in the 
table 15. Risk difference and risk ratio for short-term treatment failure were 0.06 [-0.03-0.15; 
exact-p=0.06] and 8.48 [1.24-57.97; exact-p=0.06], respectively. 
     Baseline characteristics of subjects who experienced (n=4) and who did not experience short-
term treatment failure (n=271) were also compared. In the bivariable analysis, we found that 
short-term treatment failure was significantly associated with Asian race (p=0.04) and with 
underlying cerebrovascular disease (p=0.01). Additionally, having cardiovascular disease was 
slightly more prevalent among subjects who experienced short-term treatment failure, but this 
finding did not meet statistical significance. Table 16 shows baseline characteristics among 
subjects who experienced and who did not experience short-term treatment failure. 
          To explore confounding and interaction, we performed additional analysis including 
stratified analysis, building a multivariable model by including several potential confounders with 
and without interaction terms as well as building a propensity score-adjusted model. Results of 
these additional analyses are shown in table 17.   
     In the stratified analysis of subjects with and without at least one underlying disease, the crude 
RR [8.48; 95% CI = 1.24-57.97] was significantly different from the Mantel-Haenzel (MH)-
combined RR [7.79; 95%CI = 1.16-52.39] with the MH p-value of 0.02. However, the difference of 
the crude RR and the summary RR was only 8%, and did not reach our pre-specified value 
(>15%) for determining significant confounding.   
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The stratified analysis on the underlying cerebrovascular disease (CVD) was also performed.  
The MH-combined RR of the underlying CVD [7.12; 95% CI=1.20-42.10] was also significantly 
different from the crude RR with the MH p-value of 0.04. The difference between the crude vs. 
summary RR of this variable was 16%, which reached the pre-specified value for the significant 
confounder. 
     Multivariable analysis was also performed to explore the effect of potential confounders and 
effect modifiers. By adding the variable of underlying CVD into the multivariable model, the odds 
ratio (OR) of high MIC-FQ susceptibility increased from 9.04 [95% CI=1.22-66.77; p=0.03] to 9.73 
[95% CI=1.11-85.16; p=0.04]. However, adding the variable of having at least one underlying 
disease into the final model reduced the OR of the high MIC-FQ susceptibility to 8.53 [95% 
CI=1.14-63.96; p=0.04]. The model with an interaction term between the high MIC-FQ 
susceptibility and the variable of underlying CVD did not reach statistical significance. The model 
with an interaction term between the high MIC-FQ susceptibility and the variable of having at 
least one underlying disease did not convert.  We did not include both potential confounders into 
the same model because they were collinear.  
     In addition to the stratified analysis and the multivariable analysis, we also built a propensity 
score model to predict the probability of being infected with the high MIC-FQSEC strain or the low 
MIC FQSEC strain. Due to a very low number of events in each underlying category, we failed to 
build a good predicting model. Therefore, it was impossible to reliably perform the propensity-
score-adjusted analysis.  
     Since there is no standard MIC value to distinguish low MIC-FQSEC from high MIC- FQSEC, 
we additionally performed the sensitivity analysis by changing the levofloxacin MIC cut-off value 
for low MIC-FQ susceptibility from ≤0.12 to ≤ 0.25 mcg/mL. By using the new cut-off, a total of 
252 subjects were classified into the low MIC group and 23 subjects were classified into the high 
MIC group. Two from 252 subjects in the low MIC group and two from 23 subjects in the high 
MIC-group experienced short-term treatment failure (0.8% vs. 8.7%, p=0.04). Risk difference and 
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risk ratio for short-term treatment failure between two groups were 0.08 [-0.40 -0.19; p=0.002] 
and 10.96 [1.62-74.21; p=0.002], respectively.  
     To explore the impact of misclassification, we performed sensitivity analysis on the various 
degree of differential and non-differential misclassification of outcomes. Table 18 shows the true 
effect estimates if non-differential misclassification or differential misclassification exists. In all 
hypothesized situations, the observed effect estimates were underestimated. Therefore, it is 
unlikely that the impact of high MIC-FQ susceptibility will go to the null.    
 
3. DISCUSSION 
Our study revealed that subjects with high MIC-FQSEC-UTIs were approximately 8 times more 
likely to experience treatment failure when received FQ therapy when comparing to those with 
low MIC FQSEC-UTIs  (unadjusted RR=8.48 [1.24-57.97; exact-p=0.06]). Additionally, the 
variable of underlying CVD was documented as the significant confounder in our stratified 
analysis.     
     Results from the multivariable analysis revealed that the adjusted OR of the high MIC variable 
was comparable to the unadjusted OR. By adjusting with the variable of underlying CVD, the 
adjusted OR increased from 9.04 [95% CI=1.22-66.77; p=0.03] to 9.73 [95% CI=1.11-85.16; 
p=0.04]. Including the variable of having at least one underlying disease into the final model 
reduced the OR of the high MIC-FQ susceptibility to 8.53 [95% CI=1.14-63.96; p=0.04]. There 
was no evidence of interaction between these variables.   
 To support our significant findings, we also performed the sensitivity analysis of the MIC 
cut-off value as well as the sensitivity analysis of degree of misclassification. Results from both 
sensitivity analyses confirmed that the negative impact of the high MIC-FQ susceptibility is very 
unlikely to go to the null.  
     We believe that our study is superior to other previous studies in several aspects. First, our 
study definition to identify ambulatory UTIs has shown promising discrimination ability in our 
validation study. For this reason, only subjects with the real ambulatory UTIs were enrolled into 
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our study. Although the negative impact of high MIC-FQ susceptibility on treatment response to 
FQ therapy has been previously documented in infections caused by Salmonella enterica serovar 
Typhi (S. typhi),
59,60
 our study was the first study exploring the impact of high MIC-FQ 
susceptibility on UTIs caused by E. coli pathogen.  Furthermore, we exclusively focused only on 
ambulatory UTIs among women because the treatment response might vary across sites of 
infection and clinical settings.  
     Our study had several potential limitations. Since the subjects with high MIC-FQSEC-UTI may 
be sicker than subjects with low MIC-FQSEC UTI, this may result in a higher rate of treatment 
failure among the high MIC group. Therefore, we performed stratified analysis as well as 
multivariable analysis to explore this issue.    
     A major source of information bias in a cohort study is misclassification of the outcome.  
Although we used the specifically designed criteria to detect treatment failure, it is still possible 
that we may overlook some failure events. Since subjects who experience treatment failure may 
seek a second opinion at another medical provider, treatment failure could be underestimated. To 
address this issue, we also performed chart-review to identify documented off-network visit and 
treatment failure. Of these 275 study subjects, there was only one documented off-network visit 
occurred within the first 3 months after the index date. This off-network visit occurred in the low 
MIC group (0.4%, 1/275) and it was not correlated to the UTI episode. Therefore, information bias 
due to off-network visit should be very minimal. In addition to chart-review, we performed the 
sensitivity analysis to identify the true effect estimates in case non-differential or differential 
misclassification does exist. The sensitivity analysis revealed that the true effect estimates get 
bigger in the presence of either non-differential or differential misclassification.    
     Another potential limitation is generalizability. This study primarily focused on female subjects 
with non-recurrent ambulatory FQSEC-UTIs. Therefore, the results of this study would not be 
applicable to recurrent UTIs, UTIs caused by other pathogens, other sites of infection as well as 
UTIs in the non-ambulatory setting.  
47 
 
 The last important limitation is our unexpectedly small sample size. Based on this small 
sample size, we do not have a sufficient power to identify the difference if the baseline treatment 
failure is higher than 5% and the difference in treatment failure is less than 20%. Nevertheless, 
we believe that it is not clinically meaningful if the difference in treatment failure is less than 20%.  
     In conclusion, our study was the first study demonstrating the negative impact of the high MIC-
FQ susceptibility on the treatment response among female subjects with ambulatory UTIs caused 
by E. coli who received FQ therapy. We believe that the negative impact of high MIC-FQSEC 
may be more intensified in more serious clinical situations such as nosocomial UTIs, complicated 
intra-abdominal infections or bacteremia. Future studies in other clinical settings  should be 
conducted to fill the gap of knowledge. 
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4. TABLES 
Table 12. Power calculation for the expected sample size  
Treatment failure in the low vs. high MIC group Difference Power if N= 390/3900 
1%  vs. 2% 1% 0.38 
1%  vs. 3% 2% 0.80 
1%  vs. 4% 3% 0.95 
1%  vs. 5%  4% 0.99 
1%  vs. 6% 5% 1.00 
5%  vs. 6%  1% 0.13 
5%  vs. 7% 2% 0.37 
5%  vs. 8% 3% 0.65 
5%  vs. 9% 4% 0.85 
5% vs. 10% 5% 0.95 
 
Table 13. Power calculation for the real sample size  
Treatment failure in the low vs. high MIC group Difference Power if N= 29/246 
1% vs. 16% 15% 0.85 
2% vs. 17% 15% 0.80 
3% vs. 18% 15% 0.76 
4% vs. 19% 15% 0.72 
5% vs. 20% 15% 0.70 
1% vs. 21% 20% 0.93 
2% vs. 22% 20% 0.91 
3% vs. 23% 20% 0.89 
4% vs. 24% 20% 0.87 
5% vs. 25% 20% 0.84 
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Table 14. Baseline characteristics of the low MIC group and the high MIC group 
Variables 
Low MIC (N=246) High MIC (N=29) 
p-value 
N % N % 
Baseline Characteristics 
Age (Mean+/-SD) 55.62+/-22.69 59.51+/-20.75 0.38 
Age (Median, range) 55 (18-99) 64 (18-89) 0.35 
Year of enrollment 
     
2008 82 33.3 9 31.0 0.8 
2009 131 53.3 15 51.7 
 
2010 33 13.4 17.2 16.1 
 
Race 
     
White 89 36.2 15 51.7 0.14* 
Black 141 57.3 11 37.9 
 
Asian 4 1.6 1 3.5 
 
Other/unknown 12 4.9 2 6.9 
 
Co-morbidity 
 Charlson index (mean +/-SD) 0.33+/-0.66 0.45+/-0.78 0.37 
 Charlson index (median, range) 0 (0-2) 0 (0-2) 0.44* 
 Having at least one Charlson 
conditions 
54 22.0 8 27.6 0.49 
 Acute myocardial infarction 4 1.6 1 3.5 0.43* 
 Congestive heart failure 8 3.3 3 10.3 0.10* 
 Peripheral vascular disease 6 2.4 0 0.0 0.99* 
 Cerebrovascular disease 12 4.9 2 6.9 0.65* 
 Dementia 3 1.2 0 0.0 0.99* 
 COPD 14 5.7 1 3.5 0.99* 
 Rheumatoid disease 1 0.4 0 0.0 0.99* 
 Peptic ulcer 1 0.4 0 0.0 0.99* 
 Mild liver disease 0 0.0 1 3.5 0.11* 
 Moderate/severe liver disease 0 0.0 0 0.0 … 
 Diabetes 3 1.2 1 3.5 0.36* 
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Note: * p-value from the non-parametric test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Diabetes without complication 2 0.8 0 0.0 0.99* 
 Diabetes with complication 1 0.4 1 3.5 0.20* 
 Hemiplegia or paraplegia 1 0.4 0 0.0 0.99* 
 Renal disease 6 2.4 2 6.9 0.20* 
 Cancer 12 4.9 1 3.5 0.99* 
 Metastatic cancer 7 2.9 0 0.0 0.99* 
AIDS 0 0.0 0 0.0 … 
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Table 15. Detail of treatment failure of each subjects 
Findings Low MIC High MIC 
Case 1 Case 3 Case 2 Case 4 
Type of UTIs Cystitis Cystitis Acute 
pyelonephritis 
Cystitis 
Detail of the first 
antibiotic prescription 
Ciprofloxacin 500 mg 
PO bid for 5 days 
Levofloxacin 500 mg 
PO for 7 days 
Levofloxacin 500 
mg IV od 
Ciprofloxacin 500 
mg PO bid for 7 
days 
Date of documented 
treatment failure (after 
the index date) 
Day-12 Day-8 Day-4   Day-9  
Evidence of treatment 
failure 
 Dysuria persisted on 
Day-12   
 Levofloxacin 500 mg 
PO od  for 5 days was 
prescribed on Day-12 
 Dysuria persisted on 
Day-8  
 Nitrofurantoin 100 
mg PO bid for 7 days 
was prescribed on 
Day-8   
 Persistent fever 
on Day-4 
 Levofloxacin was 
discontinued and 
cefipime was 
prescribed 
 Dysuria persisted 
on Day- 9   
 Ciprofloxacin 500 
mg bid for 7 days 
was represcribed 
on Day-9 
Repeated urine culture Yes  (on Day-12) No No No 
Results of repeated 
urine culture 
Normal flora - - - 
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Table 16. Baseline characteristics among subjects who experienced and who did not experience 
short-term treatment  
Variables 
No Failure (n=271) Failure (n=4) 
p-value 
N % N % 
Age (Mean +/-SD) 55.89 +/-22.51 65.75 +/- 21.31 0.38 
Age (Median, range) 57 (18-99) 65.5 (45-87) 0.37* 
Year of enrollment 
     
 2008 89 32.8 2 50.0 0.80* 
 2009 144 53.1 2 50.0 
 
 2010 38 14.0 0 0.0 
 
Race 
     
 White 101 37.3 3 75.0 0.04* 
 Black 152 56.1 0 0.0 
 
 Asian 5 1.9 0 0.0 
 
 Other/unknown 13 4.8 1 25.0 
 
Co-morbidity 
 Charlson index (mean +/-SD) 0.34+/-0.67 0.75+/-0.96 0.23 
 Charlson index (median, range) 0 (0-2) 0 (0-2) 0.19* 
 Having at least one Charlson 
conditions 
60 22.1 2 50.0 0.22* 
 Acute myocardial infarction 4 1.5 1 25.0 0.07* 
 Congestive heart failure 11 4.1 0 0.0 0.99* 
 Peripheral vascular disease 6 2.2 0 0.0 0.99* 
 Cerebrovascular disease 12 4.4 2 50.0 0.01* 
 Dementia 3 1.1 0 0 0.99* 
 COPD 15 5.5 0 0 0.99* 
 Rheumatoid disease 1 0.4 0 0 0.99* 
 Peptic ulcer 1 0.4 0 0 0.99* 
 Mild liver disease 1 0.4 0 0 0.99* 
 Moderate/severe liver disease 0 0 0 0 .. 
 Diabetes 4 1.5 0 0 0.99* 
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Note: * p-value from the non-parametric test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Diabetes without complication 2 0.7 0 0 0.99* 
 Diabetes with complication 2 0.7 0 0 0.99* 
 Hemiplegia or paraplegia 1 0.4 0 0 0.99* 
 Renal disease 8 3.0 0 0 0.99* 
 Cancer 13 4.8 0 0 0.99* 
 Metastatic cancer 7 100.0 0 0 0.99* 
 AIDS 0 0 0 0 ... 
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Table 17. Results from stratified analysis and multivariable analysis of factors associated with the 
short-term treatment failure 
Note. *CVD stands for cerebrovascular disease 
 
 
 
1. Stratified analysis Subgroup RR [95%CI] 
MH P-
value 
1.1 Having at least one underlying 
diseases 
  
 
Yes 6.75 [0.47-97.52] 
 0.02 
No 9.14 [0.59-140.88] 
Crude 8.48 [1.24-57.97] 
MH-Combined 7.79 [1.16-52.39] 
1.2 Having underlying of CVD* 
 
 
 
Yes 6.00 [0.58-61.84] 
 0.04 
No 8.67 [0.56-134.63] 
Crude 8.48 [1.24-57.97] 
MH-Combined 7.12 [1.20-42.10] 
2.     Model Variables in the model OR [95%CI] 
P-
value 
2.1 Simple logistic regression model  High MIC 9.04 [1.22-66.77] 0.03 
2.2 Simple logistic regression model Having underlying CVD* 21.58 [2.80-166.60] <0.001 
2.3 Simple logistic regression model Having at least one underlying diseases 3.52 [0.49-25.49] <0.001 
2.4 Multiple logistic regression model   High MIC 9.73 [1.11-85.16] 0.04 
Having underlying CVD* 23.03 [2.61-203.49] 0.005 
2.5 Multiple logistic regression model   High MIC 8.53 [1.14-63.96] 0.04 
Having at least one underlying diseases 3.22 [0.43 -24.15] 0.26 
2.4 Multiple logistic regression model   High MIC 8.96 [0.54-147.56] 0.13 
Having underlying CVD* 21.28 [1.24-361.46] 0.04 
Interaction term 1.23 [0.01-104.14] 0.93 
2.6 Multiple logistic regression model   High MIC ... Model 
did not 
convert 
Having at least one underlying diseases ... 
Interaction term ... 
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Table 18. True effect estimates if non-differential misclassification or differential misclassification 
exists 
Pattern of 
Misclassification 
High MIC 
(N=29) 
Low MIC 
(N=246) 
Risk 
Difference 
Risk 
Ratio 
Fail Not 
Fail 
Fail Not 
Fail 
Observed outcomes 2.0 27.0 2.0 244.0 0.06 8.48 
       
Non-differential 
misclassification 
      
10% 10% 2.2 26.8 2.2 243.8 0.07 8.48 
20% 20% 2.5 26.5 2.5 243.5 0.08 8.48 
30% 30% 2.9 26.1 2.9 243.1 0.09 8.48 
40% 40% 3.3 25.7 3.3 242.7 0.10 8.48 
50% 50% 4.0 25.0 4.0 242.0 0.12 8.48 
       
Differential 
misclassification 
      
20% 10% 2.5 26.5 2.2 243.8 0.08 9.64 
30% 20% 2.9 26.1 2.5 243.5 0.09 9.84 
40% 30% 3.3 25.7 2.9 243.1 0.10 9.65 
50% 40% 4.0 25.0 3.3 242.7 0.12 10.28 
        
10% 20% 2.2 26.8 2.5 243.5 0.07 7.46 
20% 30% 2.5 26.5 2.9 243.1 0.07 7.31 
30% 40% 2.9 26.1 3.3 242.7 0.09 7.45 
40% 50% 3.3 25.7 4.0 242.0 0.10 7.00 
 
METHOD-BASED PROJECT 
56 
 
Project 3: A comparison of the case-control study vs. the case-case-control study to 
investigate risk factors for antimicrobial resistance in simulated population 
1. ABSTRACT 
BACKGROUND: Nowadays, the case-control study is the most common study design used for 
exploring risk factors for antimicrobial resistance. The newer approach "case-case-control” study 
has been proposed to be a better alternative design to identify risk factors for antimicrobial 
resistance. Thus far, the conventional case-control (CC) approach and the novel case-case-
control (CCC) approach have never been quantitatively contrasted and compared.   
METHODS: A study investigating risk factors for infection caused by FQ resistant pathogen was 
used as a standard model in our simulation study. We evaluated both the CC approach and the 
CCC approach across 432 reasonable clinical situations. In each clinical situation, 500 simulated 
datasets were created by Monte Carlo simulation and subsequently used for conducting a case-
control study. Effect estimates of previous FQ exposure on infection caused by FQR pathogen 
from both approaches were quantitatively compared. 
RESULTS: Based on data from our study, the effect of prior fluoroquinolone (FQ) exposure (X) 
on the FQ-resistant infection identified by the CC approach is remarkably different from those 
identified by the CCC approach. The difference is more pronounced if the study was conducted in 
healthy population, with a lower colonization rate of 10% and no protective effect of FQ exposure 
on mechanism of harboring FQ-susceptible pathogen.  
CONCLUSION: These findings support the results in previous literatures which concluded that 
the CC approach almost always overestimates the effect of previous antibiotic exposure. 
However, that the difference between the CC and the CCC approaches would be significant only 
when the protective effect of exposure on mechanism of harboring FQ-susceptible pathogen (A1) 
does not exist. Furthermore, this difference is more pronounced in healthy population with a low 
colonization rate which a number of subjects who have FQ-susceptible and FQ-resistant 
colonization should be very low..  
2. BACKGROUND 
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Emergence of antimicrobial resistance is considered a global health problem. Knowing risk 
factors for antimicrobial resistance is an essential step in reducing the spread of antibiotic-
resistant pathogens. Currently, the case-control study is the most common study design used for 
exploring risk factors for antimicrobial resistance. The newer approach "case-case-control” study 
has been proposed to be a better alternative design to identify risk factors for antimicrobial 
resistance. Thus far, the conventional case-control (CC) approach and the novel case-case-
control (CCC) approach have never been quantitatively contrasted and compared.   
Mechanisms of infection
4,29,80
 
To accurately explore risk factors for developing infection caused by resistant pathogens, it is 
necessary to understand mechanisms of infection. Two necessary steps are required in 
developing of infection include: 1) harboring a causative pathogen, and 2) being infected by that 
particular pathogen. A model of infection caused by fluoroquinolone-resistant (FQR) and 
fluoroquinolone-susceptible (FQS) bacteria are used as an example here. The mechanisms of 
infection and other associated factors are shown in figure 1.   
     An individual can harbor FQS bacteria via mechanism-1 while mechanism-2 and mechanism-3 
are for harboring FQR bacteria. For the mechanism-1, an individual harbors only FQS bacteria. 
For the mechanism-2, an individual directly harbors FQR bacteria from either direct or indirect 
transmission.  The mechanism-3 starts when an individual harbors FQS bacteria, then these 
particular bacteria become resistant to FQ either by intrinsic mutation or acquisition of resistance 
genes from other pathogens. These bacteria may come from either exogenous source (e.g. 
droplet transmission of Streptococcus pneumoniae) or endogenous source (e.g. fecal 
colonization of Enterobacteriacae spp.). After harboring a causative pathogen, the next step for 
developing infection is being infected by these causative bacteria. An individual with FQR 
bacteria may later be infected by these FQR bacteria. It is possible that this individual may be 
free of infection caused by these bacteria his/her entire life. Similarly, an individual who harbored 
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FQS bacteria may or may not be infected by these FQS bacteria. However, it is impossible for an 
individual who does not harbor any bacteria to develop infection.  
Conventional case-control study  
A conventional case-control design has been widely accepted as a valid approach to explore risk 
factors for antimicrobial resistance. A conventional analysis approach for this design is comparing 
the resistant cases (patients with infection caused by a resistant pathogen) to the susceptible 
controls (patients with infection caused by a susceptible pathogen). When the resistant cases are 
compared with the susceptible controls, the effect estimate of a particular risk factor represents 
the likelihood of being infected by the resistant strains for the infected individual who has that 
given factor. In this study design, previous exposure to a particular antibiotic is almost always 
found to be a risk factor for resistance of that particular antibiotic. This is the results of a 
combination of two effects—the effect of antibiotic exposure in selecting for resistant pathogens 
(increasing the frequency of cases) and the protective effect of the exposure in reducing the 
frequency of controls. For example, receiving FQ therapy prior to the time of culture can inhibit 
growth of FQS pathogens. Thus, if this person develops a clinical infection (which usually arise 
from an organism colonizing the individual), they are less likely to be infected with FQS bacteria.  
This person is unlikely to develop infection caused by FQS because he/she is less likely to be 
colonized with FQS bacteria. Therefore, the effect of previous FQ therapy on the population risk 
of a FQR infection may be overestimated in the conventional case-control study. These 
limitations have been widely discussed over the past decade.
81-83
      
Novel approach, “Case-case-control study”  
Kaye et al. proposed a novel study design, “the case-case-control study” as an alternative 
approach to the standard case-control study. The goal of the new design is to draw more 
accurate conclusions on risk factors for resistant infection.
83
 In addition to comparing the resistant 
cases with the uninfected controls, they suggested comparing the susceptible cases to the 
uninfected controls.  When the resistant cases are compared with the uninfected controls, the 
combined risk factors for infection with the pathogen of interest in general, and infection caused 
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by the resistant strains specifically, are identified. When the susceptible cases are compared with 
the uninfected controls, the risk factors for developing infection caused by the pathogen of 
interest in general are identified. By comparing and contrasting the results from these two models 
qualitatively, the risk factors specifically associated with infection caused by resistant strain are 
potentially identified.   
Relative Merits of each approach 
Results from the CC approach directly address the question of “if a patient develops an infection, 
what are the risk factors for that infection being FQ resistant”. As a predictive model, it might also 
assist clinicians in selecting antibiotic therapy before the full susceptibility profile of the pathogen 
is known. The CCC approach directly answers the question “what are the risk factors for FQR 
infection among the population at risk of the infection”. This question may be of greater interest to 
healthcare epidemiologists to implement an effective program to prevent spreading of resistant 
organisms. 
     Although a number of epidemiology experts have widely explored the limitations of the CC 
approach
82-84
, all of them only qualitatively compared the results from the CC approach to the 
CCC approach. To date, there has never been any studies that quantitatively compare and 
contrast the results from these two approaches.   
     This study was conducted to evaluate the CC vs. CCC approach in investigating risk factors 
for antimicrobial resistance which will help researchers select the best approach to identify risk 
factors for antimicrobial resistance. This valuable knowledge is not only useful for any physician 
to take care of their patients, but also to policy makers and researchers. 
 
 3. METHODS 
A study investigating risk factors for infection caused by FQ-resistant pathogen was used as a 
standard model in our simulation study. We evaluated both the CC approach and the CCC 
approach across 432 reasonable clinical situations. In each clinical situation, 500 simulated 
datasets were created by Monte Carlo simulation and subsequently used for conducting a case-
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control study. Effect estimates of previous FQ exposure on infection caused by FQR pathogen 
from both approaches were quantitatively compared.  
3.1 Synthetic cohort population 
Characteristics of our synthetic cohort population were pre-specified to mimic baseline 
characteristics of subjects from previous studies investigating risk factors for antimicrobial 
resistance.  
1) Structures of the synthetic cohort population  
Synthetic cohort population with the multinomial outcome (no infection (Y=0), infection 
caused by FQS bacteria (Y=1) and infection caused by FQR bacteria (Y=2)) and binary 
primary exposure (absence (X=0) or presence (X=1) of previous FQ exposure) was 
specifically generated for this study.  
     As mentioned above, development of infection requires two essential steps; harboring a 
causative pathogen and being infected by that particular pathogen. We created three 
binomial variables, A1, A2 and A3 to represent the mechanism of harboring the causative 
pathogen 1, 2 and 3, respectively. It is possible that an individual may not harbor any 
pathogens at all (A1=0, A2=0, A3=0).  Also, the mechanism-2 and 3 may be presented in 
the same individual (A2=1 and A3=1). However, we did not allow the mechanism-1 to 
simultaneously present with the mechanism-2 or 3. Variable B represents the infection 
status of patients which was coded as no-infection (B=0) and having infection (B=1).  
     Two additional covariates were also created. We generated the covariate-1 (C1) as a 
continuous variable to represent the subject’s age (mean+/-SD) and the covariate-2 (C2) as 
a binary variable to represent the absence (C2=0) or presence (C2=1) of underlying 
disease(s). Structure of the synthetic cohort population is shown in figure 2. 
2) Population characteristics and pre-specified variables 
The population size was set to 100,000 subjects while the sample size was set to 200 
subjects per group. Since a study investigating antimicrobial resistance can be done either 
in healthy population or sick population, therefore we generated two separated sets of 
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population; 1) the healthy population and 2) the sick population. Characteristics of both 
population sets are shown in table 19. 
     Data from previous studies of ambulatory UTIs caused by E. coli
40,43,45
  was used to pre-
specify several key parameters including the prevalence of infection among the overall 
population, the prevalence of FQR infection among infected individual, the prevalence of 
prior FQ exposure among the overall population as well as population's characteristics.  
3.2 Clinical situations 
To identify all reasonable clinical situations, three important aspects need to be considered. The 
first aspect is the colonization rate, which usually varies across the causative pathogen. Second 
is the proportion of mechanism-2: mechanism-3 (A2:A3) which may be different across clinical 
situations. Lastly, the true pattern of association between X, B, A1, A2 and A3 which is still 
uncertain, therefore all possible patterns of association should be evaluated.  Details of these 
three important aspects are explained below.  
1) Colonization rate 
Given that the colonization rate usually varies across the causative pathogen, the 
colonization rate was set to 10% and 100% as shown in table 20.  The colonization rate of 
100% is suitable for any pathogen which is considered a normal flora in human (i.e. enteric 
E. coli), while the colonization rate of 10% is more suitable for other non-local organisms.    
2) Proportion of mechanism-2:mechanism-3 
The proportion of mechanism-2: mechanism-3 (A2:A3) may differ across clinical situations. 
For instance, the mechanism-2 is likely to be the main mechanism of harboring resistant 
pathogen in an outbreak of Methicillin-Resistant Staphylococcus aureus (MRSA) surgical 
site infections. On the other hand, the main mechanism of harboring resistant pathogen 
among patients with chronic obstructive lung disease who developed penicillin-resistant 
Streptococcus pneumoniae (PRSP) pneumonia should be the mechanism-3. For this 
reason, the proportion of mechanism-2: mechanism-3 was set to 10:90, 50:50 and 100:0 
as shown in the table 20.  
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3) Patterns of association and base equation (BE) 
Four base equations were used to determine the association between the primary 
exposure, the primary outcome as well as covariates. All base equations are shown below 
and the pre-specified values for their corresponding beta-coefficients are demonstrated in 
table 21.  
  Base equation-1: association between C1 and C2   
   BE-1:  logit p (C2) = β0+ β1C1  
  Base equation-2: association between C1, C2  and X  
   BE-2:  logit p (X) = β0+ β1C1+ β2C2   
  Base equation-3: association between An and X (n=1, 2, and 3) 
   BE-3: logit p (An) = β0+ β1C1+ β2C2+ β3X   
  Base equation-4: association between B and X   
   BE-4:  logit p (B) = β0+ β1C1+ β2C2+ β3X   
All variables (X, A1, A2, A3 and B) were set to be positively associated with both covariates 
(C1 and C2) with a beta-coefficient of 0.69314718 [OR=2.0]. Given that the association 
between the prior FQ exposure (X) and the mechanism of harboring the FQS pathogen 
(A1) can be either negative or null, therefore the possible beta coefficients were set to -
0.69314718 [OR=0.5] and 0.00000001 [OR=1.0].  
     Prior FQ exposure (X) can have either positive effect or no effect, but not a negative 
effect, on both mechanisms of harboring the FQR pathogen (A2 and A3). Therefore, their 
possible beta coefficients were set to 0.00000001 [OR=1.0] and 0.69314718 [OR=2.0]. 
Based on the concept of selective pressure of antibiotic use, it is reasonable to believe that 
the prior FQ exposure (X) may have stronger impact on the intrinsic development of FQR 
pathogen (A3) when comparing to the mechanism of harboring extrinsic FQR pathogen 
(A2). Given this reason, the beta-coefficient of 1.0986123 [OR=3.0] was also added for an 
association between the mechanism-3 (A3) and the prior FQ exposure (X). Moreover, the 
true association between the prior FQ exposure (X) and the probability of being infected (B) 
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is still uncertain. So, the beta-coefficient of X on B was set to -0.69314718 [OR=0.5], 
0.00000001 [OR=1.0] and 0.69314718 [OR=2.0].  
Given that there were two possible colonization rates, three possible proportions of 
mechanism-2: mechanism-3 and 36 possible patterns of association (2*2*3*3 = 36), a total 
number of reasonable situations was 216 (2*3*36). Since we generated two population 
groups (healthy and sick population), a total of 432 clinical situations were evaluated.  
3.3 Monte Carlo Simulations 
Monte Carlo simulation was performed by STATA version 12.1/SE. All random variables were 
generated by using the random number function in the STATA program. Normal and uniform 
random numbers were generated by the methods derived by Knuth
85
. Initial value of random-
number was specified (set seed command) to ensure the reproducibility.  
3.3.1 Creating the synthetic cohort population 
The synthetic cohort population was created step-by-step by using the aforementioned 
base equations. Our simulation steps are described below. 
1) The continuous C1 was generated as a normally distributed variable with a mean+/-
SD of 60+/-10. 
2) By using the BE-1, the C2 was generated as a binomial variable. 
3) The binomial variable of X was then generated by using the BE-2.  
4) The BE-3 was used to generate the binomial A1, A2 and A3. Furthermore, the 
colonization rate and the proportion of A2: A3 had to be taken into account. Therefore, 
the total number of subjects with colonization must be equal to the total number of 
subjects with A1=1 or A2=1 or A3=1.  Also, the total number of subjects with A2=1 or 
A3=1 must be matched to our prespecified proportion. 
5) The new A4 variable was then generated by using information from the A1, A2 and A3. 
(A4=0 for no colonization or FQS colonization, A4=1 for FQR colonization).  
6) The binomial B was generated by using the BE-4. 
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7) At the last step, we created four variables to represent the final outcome (Y) which is 
a composite outcome of A and B 
 Y as a multinomial variable: no infection (Y=0), FQS infection (Y=1), FQR infection 
(Y=2) 
 Y1 as a binomial variable: FQS infection (Y1=0), FQR infection (Y1=1) 
 Y2 as a binomial variable: No infection (Y2=0), FQR infection (Y2=1) 
 Y3 as a binomial variable: No infection (Y3=0), FQS infection (Y3=1) 
3.3.2 Analytic approach 
For each clinical situation, we generated 500 datasets of synthetic cohort population for 
conducting a case-control study by the CC approach as well as the CCC approach.  
Effect estimates from each approach, each simulated data set and each clinical situation 
were separately recorded. Detail of analytic approach is explained below.   
1) Conventional case-control (CC) approach  
In this approach, we conducted a case-control study by building a model comparing 
200 case subjects with FQR infection (Y1=1) to 200 control subjects with FQR 
infection (Y1=0). Cases and controls were randomly sampled from 100,000 subjects 
in the synthetic cohort population. Model building was performed using  logistic 
regression. The effect estimate (Odd Ratio) of previous FQ exposure (X) on the 
outcome of interest (Y1) was then recorded across various clinical situations.  
Model-1: logit p (Y) = β0+ β1C1+ β2C2+ β3X   
         OR for X = exp (β3) 
Where:    Y1  is a binary variable representing FQS infection (Y1=0) or FQR 
infection (Y1=1). 
C1 is a continuous variable representing subject's age (mean+/-SD)  
C2 is a binary variable representing presence (C2=1) or absence 
(C2=0) of underlying disease 
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X is a binary variable representing presence (X=1) or absence (X=0) 
of previous FQ exposure. 
 β0 is a constant term 
 β1 is a beta-coefficient for C1. 
 β2 is a beta-coefficient for C2. 
 β3 is a beta-coefficient for X. 
2) Case-case-control (CCC) approach 
We conducted a case-control study by building two separated models; First (model-
2): a model comparing 200 case subjects with FQR infection to  200 controls subjects 
without infection; Second (model-3): a model comparing 200 case subjects with FQS 
infection to 200 control subjects without infection. All study subjects were randomly 
sampled from 100,000 subjects in the synthetic cohort population. Model building 
was performed by using the same steps as the CC approach. The effect estimates 
(Odd Ratio) from the model-2 and the model-3 were separately recorded across the 
various situations. 
Model-2: logit p (Y2) = β0+ β1C1+ β2C2+ β3X    
 OR for X = exp (β3) 
Where: Y2 is a binary variable representing no infection (Y2=0) or FQR 
infection (Y2=1). 
C1 is a continuous variable representing subject's age (mean+/-SD) 
C2 is a binary variable representing presence (C2=1) or absence 
(C2=0) of underlying disease 
 X is a binary variable representing the presence (X=1) or absence 
(X=0) of previous FQ exposure. 
 β0 is a constant term 
 β1 is a beta-coefficient for C1. 
 β2 is a beta-coefficient for C2. 
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 β3 is a beta-coefficient for X. 
Model-3:logit p (Y3) = β0+ β1C1+ β2C2+ β3X   
                     OR for X = exp (β3) 
Where:  Y3 is a binary variable representing no infection (Y3=0) or FQS 
infection (Y3=1). 
C1 is a continuous variable representing subject's age (mean+/-SD) 
C2 is a binary variable representing presence (C2=1) or absence 
(C2=0) of underlying disease 
 X is a binary variable representing the presence (X=1) or absence 
(X=0) of previous FQ exposure. 
 β0 is a constant term 
 β1 is a beta-coefficient for C1. 
 β2 is a beta-coefficient for C2. 
 β3 is a beta-coefficient for X. 
3) True effect of primary exposure (previous FQ exposure)  
Similar to the CC approach and the CCC approach, we evaluated the true effect of 
prior FQ exposure (X) on the final outcome by building a multiple logistic regression 
model-1, -2 and -3. However, all subjects in the synthetic cohort population 
(n=100,000) were included into the analysis.  
3.3.3 Parameters to be evaluated 
After performing all analyses, we obtained both estimated OR and the true OR of X on 
other variables in across all possible clinical situations. Parameters to be reported are 
shown below. 
1) Estimated OR from the CC approach and the CCC approach  
The effect estimates of the prior FQ exposure (X) on outcomes of interest (Y1, Y2 or 
Y3) are presented as the odds ratio and 95% confident interval.   
2) True OR from the entire cohort population  
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The true effect of the prior FQ exposure (X) on outcomes of interest (Y1, Y2 or Y3) as 
well as the probability of being infected (B) are presented as the odds ratio and 95% 
confident interval.   
3) Model comparison 
3.1) Percent bias (PB) and Percent deviation (PD)  
  PB and PD can be calculated by using the following formula.  
  PB = estimated value - true value x 100% 
                           true value 
 
  PB = model B-estimated value - model A-estimated value x 100% 
                           model A-estimated value  
 
The PB represents the average tendency of the estimated value to be larger or 
smaller than its true value. A positive PB indicates overestimation bias while a 
negative PB indicates underestimation bias. The PD represents the average 
difference between two values. Therefore, a bigger value indicates a larger 
difference between two observed values. 
3.2) Coverage probability (CP) 
CP is the proportion of the time that the confidence interval of the estimated 
value contains the true value of interest. Ideally, the CP would be about 0.95 
(since they are based on 95% confidence intervals) 
.  
4. RESULTS 
To evaluate the CC and CCC approach, results from the following pairs of model were compared.    
4.1 Estimated effect vs. True effect 
An effect estimate of X on Y1 from the case-control study and an effect estimate of X on Y2 or Y3 
from the case-case-control study were compared to the true which was identified from the entire 
cohort population. This helps us to assess the degree of bias when conducting the case-control 
study across various clinical situations. Supplementary table 1 shows the estimated OR, the true 
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OR, the percent bias (PB) as well as the coverage probability (CP) when the estimated OR and 
the true OR were compared.   
     When we focused on the model-1 (FQR vs. FQS), the mean PB was 6.47 ± 3.79 and the 
median PB was 5.51 (range -0.75 - 22.73). The mean CP was 0.96 ± 0.01 and the median CP 
was 0.96 (range 0.93 - 0.99). The PB was higher than 20% in 5 clinical situations. However, the 
CP was higher than 80% in all clinical situations. Population characteristics and patterns of 
association of these 5 outliers are shown in the table 23. These outliers occurred in a study 
conducted among the healthy population, without the protective effect of X on A1 (beta-coefficient 
= 0.0000001) and with small effect of X on B (beta-coefficient = 0.69314718). 
     When we focused on the model-2 (FQR vs. No infection), the mean PB was 5.58 ± 2.27 and 
the median PB was 5.39 (-0.2 - 11.7). Mean CP was 0.95 ± 0.01 and the median CP was 0.95 
(0.92 - 0.98).  There was no any clinical situation that the PB was higher than 20% or the CP was 
below 80%. 
     When we focused on the model-3 (FQS vs. No infection), the mean PB was 4.75 ± 2.23 and 
the median PB was 4.47 (0.56 - 12.1). Mean CP was 0.95 ± 0.01 and the range was 0.95 (0.93 - 
0.97). There was no any clinical situation that the PB was higher than 20% or the CP was below 
80%. 
4.2 Comparison of the estimated effect from the model-1 vs. the model-2 
An effect estimate of X on Y1 from the case-control study (estimated ORY1) was compared to the 
effect estimate of X on Y2 from the case-case-control study (estimated ORY2).  This helps us to 
determine the clinical situations that the model-1 and the model-2 would provide the similar 
results.  
     Percent deviation (PD) and coverage probability (CP) between the estimated ORY1 and the 
estimated ORY2 are shown in supplementary table 2. The mean PD was 51.86 ± 80.00 and the 
median PD was 26.68 (-49.48 - 274.74). Figure 3 shows the percent deviation across all possible 
clinical situations.  The CP was 0.56 ± 0.30 and the median CP was 0.53 (0.05 - 0.96).  
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 Sensitivity analysis was subsequently performed to determine whether the PD and CP may 
vary by some specific factors.  Figure 4 shows the sensitivity analysis on the population type 
(Healthy vs. Sick population). Figure 4.1 and 2.2 present the PD from the healthy population and 
the sick population, respectively. The x-axis represents the patterns of association. The PD was 
obviously higher among the healthy population when comparing to the sick population. Nineteen 
outliers (PD>300%) are located at the left upper corner of the figure 4.1, which confirms that the 
pattern of association has significant impact on the PD.  Population characteristics and patterns 
of association of these 19 outliers are shown in the table 24.  These high bias patterns occurred 
in situations that there is no protective effect of X on A1 (beta-coefficient =0.0000001) but there is 
small effect of X on B (beta-coefficient =0.69314718). 
 Figure 5 shows the sensitivity analysis on the colonization rate (10% vs. 100). Figure 5.1 and 
5.2 reveal the PD from the population with a colonization rate of 10% and 100%, respectively. 
The PD was slightly higher among the clinical situation with the colonization rate of 100%. 
However, there were 16 outliers on the right upper corner of the figure 2.3. Population 
characteristics and patterns of association of these 16 outliers are shown in the table 25. The 
common factors among these 16 outliers included; the healthy population, there is no protective 
effect of X on A1 (beta-coefficient =0.0000001) but there is small effect of X on B (beta-coefficient 
=0.69314718). 
 
5. DISCUSSION 
Based on data from our study, an effect estimate of X on Y1 that that was identified by the CC 
approach and an effect estimate of X on Y2 or Y3 that was identified by the CCC approach were 
similar to those identified from the entire cohort population. Percent bias and coverage probability 
are within an acceptable range in nearly all clinical situations.   
     Our study revealed that the effect of prior FQ exposure (X) on the FQR infection identified by 
the CC approach is remarkably different from those identified by the CCC approach. The 
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difference was more pronounced if the study was conducted in healthy population, with a 
colonization rate of 10%, no protective effect of X on A1 but there is small effect of X on B.      
     These findings support the results in previous literatures
83,84
 which concluded that the CC 
approach almost always overestimates the effect of previous antibiotic exposure. Given that the 
difference between the CC and the CCC approaches would be significant only in situations that 
the protective effect of X on A1 does not exist. Additionally, the number of subjects who have FQS 
and FQR colonization should be very low in the healthy population with a low colonization rate. 
Therefore, the difference between these two approaches is more pronounced.  
     Our study had some potential limitations.  First, this study aimed to identify risk factors for 
antimicrobial resistance, the association between outcome and other factors were specifically 
designed by using the conceptual framework of emergence of antimicrobial resistance. 
Furthermore, most of pre-specified values were set by using data from antimicrobial resistance 
literature. Therefore, the results from our study might not be applicable to other kind of research.  
     Second, our study sample size was set at 200 subjects per group. This may be too small in 
some clinical situations. However, the average sample size of previous studies of antimicrobial 
resistance was 100-500. Therefore, this number seems to be similar to majority of previous 
studies's sample size. Third, our study methods were quiet complicated. The study results are 
probably too difficult to understand without basic knowledge in statistics.  
     In conclusion, our study confirmed that the CC approach and the CCC approach are not 
interchangeable.  The CC approach could provide answers to assist clinicians in selecting 
antibiotic therapy before the full susceptibility profile of the pathogen is known. The CCC 
approach seems to be more useful for healthcare epidemiologists to implement an effective 
program to prevent spreading of resistant organisms. Researchers should carefully choose the 
appropriate study approach to best answer their research questions. However, our study was 
specifically designed for the study investigating risk factors for antimicrobial resistance, therefore 
the results may be different in other field of research. Future study comparing the CC vs. the CCC 
approach in other fields is still needed.  
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6. TABLES 
Table 19. Characteristics of synthetic cohort population 
Baseline characteristics Healthy population Sick population 
Population size 100000 100000 
Sample size  200 200 
Colonization rate 10%, 50, 100% 10%, 50%, 100% 
Prevalence of infection among the population   5% 10% 
Prevalence of resistant infection among all infections  10% 20% 
Prevalence of FQ exposure   10% 20% 
Mean age +/-SD (year) 60+/-10 60+/-10 
Prevalence of having at least one underlying diseases     10% 20% 
 
Table 20. Variation in the colonization rate and the proportion of mechanism-2: mechanism-3 
Variation Colonization rate Proportion of mechanism-2: mechanism-3 
1  10% 10%:90% 
2  10% 50%:50% 
3  10% 100%:0% 
4  100% 10%:90% 
5  100% 50%:50% 
6  100% 100%:0% 
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Table 21. Possible patterns of association and their corresponding beta-coefficients 
Association between Range of degree of association  
(beta-coefficient) 
Dependent 
variables 
Independent 
variables 
C1 C2   0.69314718  
X C1   0.69314718  
X C2   0.69314718  
A1 C1   0.69314718  
A1 C2   0.69314718  
A2 C1   0.69314718  
A2 C2   0.69314718  
A3 C1   0.69314718  
A3 C2   0.69314718  
A1 X -0.69314718 0.00000001   
A2 X  0.00000001 0.69314718  
A3 X  0.00000001 0.69314718 1.0986123 
B X -0.69314718 0.00000001 0.69314718  
Note:  Exp (-0.69314718) =  0.5 
 Exp (0.00000001) = 1.0 
 Exp (0.69314718) = 2.0 
 Exp (1.0986123) = 3.0 
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Table 22. Comparison of the estimated effect and the true effect 
 
Parameters to be evaluated Comparison between the estimated value vs. the true value 
Model-1:  
(FQR vs. FQS) 
Model-2 
(FQR vs. No 
infection) 
Model-3 
(FQS vs. No infection) 
Mean percent bias (±SD) 6.47 ± 3.79 5.58 ± 2.27 4.75 ±2.23 
Median percent bias (range) 5.51 (-0.75 - 22.73) 5.39 (-0.2 - 11.7) 4.47 (0.56 - 12.1) 
Mean coverage probability (±SD) 0.96 ± 0.01 0.95 ± 0.01 0.95 ± 0.01 
Median coverage probability (range) 0.96 (0.93 - 0.99) 0.95 (0.92 - 0.98) 0.95 (0.93 - 0.97) 
 
 
Table 23. Population characteristics and patterns of association of clinical situations that provide 
those 5 outliers in the figure 3 (the OR of X on Y1 (model-1) with a percent bias of 20% or more) 
Clinical 
situations 
Population 
characteristics 
Colonization 
rate (%) 
Proportion  
A2:A3 
Beta-coefficient between 2 
variables* 
Percent 
bias 
A1-X A2-X A3-X B-X 
409 Healthy population 10 0.5:0.5 0.01 0.01 0.69 0.69 22.73 
337 Healthy population 10 0.1:0.9 0.01 0.01 0.69 0.69 21.98 
403 Healthy population 10 0.5:0.5 0.01 0.69 0.01 0.69 21.11 
304 Healthy population 100 0.5:0.5 0.01 0.01 0.01 0.69 21.06 
340 Healthy population 10 0.1:0.9 0.01 0.01 0.01 0.69 20.10 
Note: * approximated values  
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Table 24. Population characteristics and patterns of association of clinical situations that provide 
those 19 outliers in the figure 4.1 (Healthy population) 
Clinical 
situations Population 
characteristics 
Colonization 
rate (%) 
Proportion  
A2:A3 
Beta-coefficient between 2 
variables* 
Percent 
bias 
A1-X A2-X A3-X B-X 
259 Healthy population 100 1 0.01 0.69 0.01 0.69 219.75 
268 Healthy population 100 1 0.01 0.01 0.01 0.69 223.70 
304 Healthy population 100 0.5 0.01 0.01 0.01 0.69 219.67 
325 Healthy population 10 0.1 0.01 0.69 1.09 0.69 241.73 
331 Healthy population 10 0.1 0.01 0.69 0.01 0.69 253.27 
334 Healthy population 10 0.1 0.01 0.01 1.09 0.69 243.85 
337 Healthy population 10 0.1 0.01 0.01 0.69 0.69 270.16 
340 Healthy population 10 0.1 0.01 0.01 0.01 0.69 265.32 
361 Healthy population 10 1 0.01 0.69 1.09 0.69 245.84 
367 Healthy population 10 1 0.01 0.69 0.01 0.69 267.01 
370 Healthy population 10 1 0.01 0.01 1.09 0.69 239.58 
373 Healthy population 10 1 0.01 0.01 0.69 0.69 251.12 
376 Healthy population 10 1 0.01 0.01 0.01 0.69 256.80 
397 Healthy population 10 0.5 0.01 0.69 1.09 0.69 244.21 
400 Healthy population 10 0.5 0.01 0.69 0.69 0.69 268.21 
403 Healthy population 10 0.5 0.01 0.69 0.01 0.69 263.66 
406 Healthy population 10 0.5 0.01 0.01 1.09 0.69 253.34 
409 Healthy population 10 0.5 0.01 0.01 0.69 0.69 274.74 
412 Healthy population 10 0.5 0.01 0.01 0.01 0.69 263.81 
Note: * approximated value 
 
 
 
 
 
 
75 
 
Table 25. Populations characteristics and patterns of association of clinical situations that provide 
those 16 outliers in the figure 5.1 
 
Clinical 
situations 
Population 
characteristics 
Colonization 
rate (%) 
Proportion  
A2:A3 
Beta-coefficient between 2 
variables* 
Percent 
bias 
A1-X A2-X A3-X B-X 
325 Healthy population 10 0.1 0.01 0.69 1.09 0.69 241.73  
331 Healthy population 10 0.1 0.01 0.69 0.01 0.69 253.27  
334 Healthy population 10 0.1 0.01 0.01 1.09 0.69 243.84  
337 Healthy population 10 0.1 0.01 0.01 0.69 0.69 270.16  
340 Healthy population 10 0.1 0.01 0.01 0.01 0.69 265.31  
361 Healthy population 10 1 0.01 0.69 1.09 0.69 245.84  
367 Healthy population 10 1 0.01 0.69 0.01 0.69 267.01  
370 Healthy population 10 1 0.01 0.01 1.09 0.69 239.57  
373 Healthy population 10 1 0.01 0.01 0.69 0.69 251.12  
376 Healthy population 10 1 0.01 0.01 0.01 0.69 256.79  
397 Healthy population 10 0.5 0.01 0.69 1.09 0.69 244.21  
400 Healthy population 10 0.5 0.01 0.69 0.69 0.69 268.20  
403 Healthy population 10 0.5 0.01 0.69 0.01 0.69 263.66  
406 Healthy population 10 0.5 0.01 0.01 1.09 0.69 253.34  
409 Healthy population 10 0.5 0.01 0.01 0.69 0.69 274.74 
412 Healthy population 10 0.5 0.01 0.01 0.01 0.69 263.81 
Note: * approximated value 
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7. FIGURES 
Figure 1. Mechanisms of developing infection 
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Figure 2. Structure of the synthetic cohort population  
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Figure 3. Percent deviation between the estimated ORY1 and the estimated ORY2 across all 
clinical situations 
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Figure 4 Percent deviation by the population type (Healthy vs. Sick population)  
Figure 4.1  Healthy population, by patterns of association 
 
 
Figure 4.2 Sick population, by patterns of association 
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Figure 5 Percent deviation by the colonization rate (10% vs. 100%)  
Figure 5.1  Colonization rate =10%, by patterns of association 
 
 
Figure 5.2  Colonization rate =100%, by patterns of association 
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DISSERTATION CONCLUSION 
This dissertation project consisted of three related studies exploring the problem of emergence of 
fluoroquinolone resistance. Two content-based studies focused on the high MIC fluoroquinolone-
susceptible E. coli (FQSEC) which may serve as an important reservoir for FQ resistance. A 
method-based study evaluated two case-control approaches in investigating risk factors for 
antimicrobial resistance.  
 The first study was a case-control study conducted to identify risk factors for high MIC-FQ 
susceptibility among female subjects with urinary tract infections (UTIs) caused by FQSEC. 
Independent risk factors identified in this study included Asian race, having renal diseases and 
previous exposure to nitrofurantoin. These findings could not be explicitly explained. Future 
studies need to be done to explore these interesting findings. 
 The second study was a cohort study of female subjects with ambulatory FQSEC-UTIs 
who were treated with FQ therapy. Adjusted analysis revealed that treatment failure in the high 
MIC group was 8 times higher than those in the low MIC group. Therefore, the current MIC 
breakpoint for FQ susceptibility in E. coli uropathogen may need to be revised. Our study results 
would be useful for those reevaluating breakpoints.   
  In the method-based study, we quantitatively compared the conventional case-control 
(CC) approach and the novel case-case-control (CCC) approach in investigating risk factors for 
infection caused by FQ-resistant pathogen in the simulated setting. Our study confirmed that the 
CC approach almost always overestimates the effect of previous antibiotic exposure. The 
difference is more pronounced if the study is to be conducted among healthy population with a 
lower rate of colonization and protective effect of exposure on mechanism of harboring FQ-
susceptible pathogen does not exist. Therefore, researchers should carefully choose the 
appropriate study approach to best answer their research questions.   
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